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Abstract
Objective: To identify baseline variables predictive of severity of pediatric-onset
Crohn's disease during the first year following diagnosis.
Study Design: Prospective inception cohort study.
Participants/Setting: Pediatric patients (aged <17 years) newly dia~nosed with Crolm's
disease at the Hospital for Sick Children, Toronto, Canada from July 1997 - May 2001.
Methods: The primary outcome variable was disease severity as measured by Physicians
Global Assessment (quiescent/mild, moderate/severe). The influence of pre-selected
baseline variables (gender, disease location, laboratory parameters, initial corticosteroid
therapy, response to initial therapy and PCDAl scores) on disease severity was
determined by multivariate analysis.
Results: In follow-up of 122 patients, 73 had quiescent/mild disease and 49
moderate/severe disease. Univariate analysis demonstrated moderate/severe disease was
associated with low albumin (p=0.004), high PCDAl (p<O.OO 1), initial hospitalization
(p=0.004), initial corticosteroids use (p=0.003) and partial/no response to initial therapy
(p=0.028). In multivariate regression analysis, PCDAI score was the best single predictor
of subsequent disease severity (p<O.OOl, R2=0.16).
Conclusion: Disease activity at diagnosis is predictive of disease severity during the first
year in pediatric-onset Crolm's disease.
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Chapter 1 - INTRODUCTION
1.1 INTRODUCTION
Crohn's disease (CD) is an idiopathic chronic relapsing disorder of the
gastrointestinal tract. It is a heterogeneous conditio.n with considerable variability noted
1
both in its phenotypic expression and clinical course. Up to 25 peteent of cases present
I
during childhood and adolescence (1) and can be associated with sigrllificant morbidity as
manifested by debilitating symptoms, frequent hospitalizations, growth retardation and
need for surgical interventions (2-4). Despite the wide range in clinical course, little
work has been done to identify prognostic factors of disease severity.
In the subsequent pages, the current understanding of the etiology and
epidemiology of Crohn's disease will be reviewed with a focus on pediatric-onset disease.
Studies describing the clinical course and associated morbidity of Crolm's disease will be
critically analyzed, so as to determine the spectrum of illness associated with this
condition. Current therapeutic algorithms will be presented with emphasis placed on the
evolution of new therapeutic paradigms and how treatment selection is determined in part
by disease activity and severity. Finally, studies conducted to identify prognostic factors
of disease severity will be reviewed, as such information may prove important in the
selection of the most appropriate therapeutic modalities for any individual patient. This
discussion will form the foundation for the argument defending the purpose of this thesis.
1.2 BACKROUND
1.2.1 Description of Crohn's Disease
Crohn's disease, together with ulcerative colitis (UC), accounts for the majority of
cases of chronic intestinal inflammation occurring jn humans. The etiology(s) has not
been identified, though accumulated evidence supports a multi-varicible model involving
,
complex interactions between genetic and environmental factors (5-9). Recent research
supports the theory that the underlying pathophysiology involves an inappropriate and
ongoing activation of the mucosal immune system propagated by the normal lwninal
flora. This aberrant response most likely develops secondary to defects in both the
barrier function of the intestinal epithelium and the mucosal immune system (10).
Crohn's disease is heterogeneous, encompassing a wide spectrum in its
phenotypic expression. Classically, patients present with the triad of symptoms of
diarrhea, abdominal pain and weight loss. However, many pediatric patients present with
growth failure, pubertal delay, iron deficiency anemia, anorexia, perianal disease or
arthritis as the predominant symptom (11).
The anatomical site of intestinal involvement also varies widely in Crohn's
disease. Six hundred ninety-two children and adolescents were evaluated at the Hospital
for Sick Children, Toronto from 1980-1999. Forty-one percent had macroscopic disease
involving the small bowel only, 40 percent had ileocolonic disease, and 19 percent had
disease limited to the colon (12). Barton et al (13) reported similar findings in pediatric-
onset Crohn's disease (small bowel only 30%, large and small bowel 38%, colon only
28%). Similarly, 30-35 percent of adults are reported to have srpall bowel disease and
25-35 percent isolated colonic disease (14). Perianal disease and fistula formation occurs
in one third of patients over time (15).
Unfortunately, no gold standard exists to confirm the diagno~is. Hence, Crohn's
I
disease is currently defined empirically on the basis of compatible olinical, radiologic,
endoscopic and histologic features, after the exclusion of other etiologies (16; 17).
Advancements in flexible endoscopy allow for easily obtainable biopsies, improving
diagnostic accuracy. Despite this, differentiation between ulcerative colitis and isolated
colonic Crohn's disease may initially be difficult in 10-15 percent of patients (18).
1.2.2 Epidemiology
The worldwide distribution of Crohn's disease and ulcerative colitis is similar,
with the highest incidence rates reported in North America (7.0-14.6/100,000) and
Northwestern Europe, especially Scandinavia (5.8-15.6/1 00,000) and the United
Kingdom (3.8-22.1/1 00,000) (19-27). Bernstein et al (20) performed a population-based
study (1989-1994) in the province of Manitoba and measured the incidence and
prevalence rates for Crohn's disease to be 14.6/1 00,000 and 198.5/1 00,000 respectively.
The incidence of Crolm's disease peaks during the second decade of life, with a
subsequent smaller rise during the fifth decade (19;28). otably, up to 25 percent of
cases clinically manifest in patients under the age of twenty (1). The majority of these
present in late childhood and adolescence, though occurrence even during infancy has
been reported (29-33). Incidence rates of pediatric-onset Crop.n's disease during the
1980's range from 1.7-2.5/100,000 and for ulcerative colitis from 0.7-4.311 00,000 (34-
36). Bernstein et a1 (20) measured the incidence rate for Crolm's disease in children <10
years of age and between 10-19 years to be 0.71109,000 and 12.71100,000 respectively.
The prevalence rate was found to be 1.771100,000 and 55.81100,~00 for children <10
years old and between 10-19 years old respectively.
Epidemiological studies have documented changes in the incidence/prevalence of
the inflammatory bowel disease (IBDs) over time. The incidence of Crolm's disease
increased sharply in all age groups in most Western populations between the 1950's and
the 1980's, while the incidence of ulcerative colitis did not change (37). A tlu'eefold rise
in the incidence of Crolm's disease among Scottish children between 1968 and 1983 and a
fourfold increase in the incidence of Crolm's disease in youth below age 19 in Sweden
between 1959 and 1974 have been reported (3). Recently, Timmer et al observed a stable
incidence of Crohn's disease in Germany from 1980 to 1995, but did note significantly
more involvement of the sigmoid and rectum over this period (38).
The variations in incidence and prevalence rates reported among the different
studies may relate to differences in the genetic and/or envirolm1ental risks of the
populations analyzed. However, introduction of measurement bias in the study design
could account for the observed variation. Measurement bias may occur at a number of
levels, including population selection, disease definition, case ascertainment, method and
quality of data selection, duration of assessment and statistical evaluation (19).
For instance, increased awareness of inflammator)r bowel disease and
improvements in diagnostic techniques, especially endoscopy, make it difficult to
compare rates between studies over time (19). Variability in health care delivery, with
limitation of diagnostic access to segments of the p0pulation may in part account for the
lower incidence rates observed in developing countries (19;39j. In general, data
collection in prospective studies is of a higher quality than that of retrospective studies
(40). In comparing incidence and prevalence rates between different regions, crude rates
can be misleading due to the age dependency. As such standardized rates should be
looked at, adjusting the crude rate for the population demographics (40).
It is important to adhere to several other principles when designing
epidemiological studies of Crolm's disease. Most importantly, population-based studies
are necessary to accurately estimate the incidence and prevalence of disease.
Unfortunately, many early studies were hospital-based and were likely to underestimate
incidence and prevalence but overestimate disease severity. The relatively long duration
between onset of symptoms and diagnosis of inflammatory bowel disease will also lead
to underestimation of incidence and prevalence during any given time period (19;41).
Consistently applied definitions of disease are also necessary. As no gold
standard exists for the diagnosis of inflammatory bowel disease, misclassification and
reclassification can be problematic. As previously noted, 10-15 percent of colitis cases
are initially classified as 'indeterminate'; and up to 3 percent of patients with Crohn's
disease or ulcerative colitis are reclassified during follow-up (19;42). Outcome variables
must be carefully selected. They must be validated and ideally stGfpdardized to facilitate
comparisons among studies.
1.3 IMPACT OF DISEASE
1.3.1 Natural History/Clinical Course
I
Crohn's disease is characterized by a pattern of exacerbatio11s and remissions.
However, there is considerable intra-patient and inter-patient heterogeneity in its clinical
course. The spectrum ranges from one of relatively mild symptoms with infrequent
exacerbations to chronic unremitting disease activity that is refractory to treatment. The
basis of the heterogeneity is unknown but may relate to different etiologies and/or disease
modifiers, either environmental and/or genetic.
Truelove et al (43) reported on the clinical course and prognosis of Crohn's
disease in a cohort retrospectively assembled using diagnostic codes from two regional
hospitals in Oxford, Britain from 1938-1970. Three hundred and three patients with
Crohn's disease were originally identified, of which 82 were excluded due to inadequate
records. One hundred sixty-six were newly diagnosed patients, the remainder being
referred for management of established disease. Of the 166 newly diagnosed patients the
mean duration of follow-up was 9.1 years. Twenty-eight patients (12.7%) were less than
20 years of age at diagnosis. Due to the prolonged period of recruitment, therapy
regiments changed quite significantly in the cohort. During the earlier years, treatment
consisted of vitamin supplements, control of diarrhea and correction of anemia. Specific
measures were introduced in the 1950s with the use of sulphasalazine and corticosteroids.
Practices with these therapies varied widely, with differing {doses and lengths of
treatment. Immunosuppressives drugs were used very infrequently during the time frame
of this study. Diagnostic criteria also differed from those currently employed, and were
based upon a compatible clinical complex with. definite radiological, operative or
histological evidence to support the diagnosis.
Relapse rate was not assessed. Seventy-four percent of new cases underwent
surgery during follow-up. Local problems included fistula formation (14.5%), abscess
(10.2%), intestinal obstruction (5.4%), perforation (1.2%) and carcinoma (2.4%). Twelve
patients died from problems of Crolm's and 5 others from probable problems of Crohn's
disease. The cumulative mortality rate for newly diagnosed Crohn's disease patients over
a I5-year follow-up was 18.0 percent, compared to 8.1 percent for age and sex matched
controls. Age did not appear to have any effect on prognosis in terms of survival over a
five-year period, though females had a cumulative fatality rate of 4.6 percent over 5 years
compared to 0.6 percent for males (newly diagnosed cases). Statistical comparisons were
not made.
While the study did illustrate the clinical course with respect to surgical
intervention and mortality relatively well, weaknesses of this study included imprecise
diagnostic criteria and failure to assess relapse and remission rates. Forty-six patients
(20.8%) did not have histology collected and this may have lead to inaccurate diagnoses.
Eight-two patients (27%) were not analyzed secondary to inadequate records and this is a
potential source of bias in assessing clinical outcomes. Furthermore, the study was
retrospective and assembled over a period of 32 years durin~.'which time treatment
regimens changed dramatically and differed significantly from those currently used. As
such, the applicability of this data to present populations is tenuous. Moreover, the study
primarily described adult-onset disease, which may preclude its generalization to
pediatric-onset disease.
In a separate study, Munkholm et al (44) described the clinical course of
inflammatory bowel disease in a regional inception cohort of 373 Crohn's disease
patients diagnosed in Copenhagen County, Denmark from 1962-1973. Only two patients
were excluded due to inadequate data. Patients were followed up regularly from
diagnosis with a mean follow-up of 8.5 years (range 0-26 years). Diagnosis was
standardized and patients were treated with combinations of sulphasalazine,
corticosteroids and surgery. Immunosuppressants were infrequently used during this
study period.
Disease activity was assessed for each year, based on the maximal activity during
that year. Disease activity was categorized as no activity, low activity or moderate/high
activity (Table 1.1). Additionally, disease course during the previous year was
categorized as relapse-free, chronic-intermittent or chronic continuous (Table 1.1).
Eighty percent of patients had high activity in the initial year of diagnosis. In
subsequent years, approximately 30 percent had high activity, 15 percent low activity and
55 percent were in clinical remission. 0 differences were noted between those patients
Table 1.1
Outcome
Disease Activity and Disease Course Definitions, ¥unkholm et al (44)
Definition
Disease Activity
- 0 Activity
- Low Activity
- Moderate/High
Activity
Disease Course
- Relapse Free Course
- Chronic Intermittent
Course
- Chronic Continuous
Course
</= 2 stools/day and no. blood or pus in the stools. No
abdominal pains and no systemic symptoms such as fever or
weight loss
<5 and >2 stools/day and/or blood or pus ~n the stools and/or
mild abdominal pain less than daily; no systemic symptoms
such as fever or weight loss
> 4 stools/day and/or passage of blood or pus daily and/or
abdominal pains either severe or daily, with (high) or without
(moderate) systemic symptoms such as fever or weight loss
No clinical activity in any year after the year of diagnosis
Either a) years with intermittent activity - that is, remission for
more than 1 month (without corticosteroid treatment) or b)
years without disease activity between years with activity
Continuous activity within and during each year of follow-up
with relapses and those in remission with regard to age, gender, year of diagnosis,
localization of Crohn's disease or histological evidence of disease.
While individual patients changed from 'year to year between relapse and
remission, disease activity in the preceding year was related to that in the subsequent
year. Seventy to 80 percent of patients with active disease in one year were observed to
have active disease in the following year. Likewise, approximately 80 percent of patients
in remission remained so the following year (Figure 1.1).
The strengths of this study are its large sample size and the fact that it is
population-based thus eliminating referral bias. Importantly the treatment was
standardized. Unfortunately, the sample size was collected over a period of 25 years
prior to the use of immunosuppressive therapy. Thus, the results may not be applicable to
present day practice where immunosuppressive are more frequently used. Additionally,
the study was predominantly adult based and therefore may not be representative of
pediatric-onset disease. Finally, the study did not attempt to identify baseline predictive
factors such as disease activity and initial response to therapy.
More recently, Faubion et al (45) studied a population-based inception cohort of
171 patients diagnosed with Crolm's disease in Olmsted County from 1970-1993 to
assess the outcomes during a one-year period in the 74 patients (43.3%) requiring the
initiation of systemic corticosteroids. Immediate outcomes were assessed at thirty days
and one year following the initiation of corticosteroids (Table 1.2).
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Figure 1.1 One-year probabilities of active disease (-- ) or remission E--) the
following year, provided: active disease the previous year (1.1a) or remission the
previous year (1.1 b). A Markov analysis (41).
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Table 1.2 Disease Activity and Disease Course Definitions, Fapbion et al (45)
Outcome Definition
Immediate Outcome
- Complete Remission Total regression of clinica~ symptoms «/~ 2 stools/day; no
blood, pus or mucus in feces; and no abdominal pain, fever,
weight loss or extraintestinal symptoms). ~
I
- Partial Remission Regression of clinical symptoms «/= 4 stools/day; blood, pus,
mucus in feces; or abdominal pain; or all 4 less than daily and
no systemic symptoms, such as fever or weight loss).
- No Response No regression of clinical symptoms.
One-Year Outcome
- Prolonged Response Maintenance of complete or partial remISSIon after steroid
therapy was completed. Patients who required subsequent
courses of steroids but maintained complete or partial response
and were steroid free at the end of 1 year were included in the
prolonged response outcome group.
- Steroid-Dependent Continued steroid therapy at year-end caused by relapse after
steroids were discontinued or caused by relapse at dose
reduction impeding discontinuation of steroid therapy. Patients
who required surgical resection (see below) and were also
steroid dependent at 1 year were counted in the surgical
resection group.
- Surgical Resection Relapse within 1 year after steroid therapy was initiated,
resulting in surgical resection.
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Forty-three patients (58%; 95% cr, 46%-69%) were in q.omplete remission, 19
(26%; 95% cr, 16%-37%) were in partial remission and 12 (16%; 95% cr, 9%-27%) had
no response after 30 days. Age, gender, interval to corticosteroid therapy from diagnosis
or disease extent were not associated with immediate outcome. Concomitant therapy
with mesalamine or sulfasalazine however, was a statistically sighificant predictor of
immediate outcome (OR 0.35 for combined partial or complete response, 95%Cr 0.13-
0.96, p=0.04).
One year after initiation of cOliicosteroid therapy, 24 patients (32%; 95% cr,
22%-44%) had sustained a prolonged response, 21 (28%; 95% cr, 19%-40%) were
corticosteroid dependent, 28 (38%; 95% cr, 27%-50%) had undergone surgical resection
and one (1 %) was lost to follow-up. No risk factor was identified to be predictive of one-
year outcome following the initiation of corticosteroid therapy.
Strengths of this study are the well-defined outcome variables and that it is
population-based. The number of patients lost to follow-up was low (1 patient). As the
study was conducted on patients diagnosed and treated before 1994, the use of
immunosuppressive therapy on the outcome of disease could not be assessed as only two
(3%) Crohn's disease patients had received immunosuppressants. Furthermore, the
cohort was not solely composed of patients with newly diagnosed disease.
rn another study, Moum et al (46) described the clinical course ofCrolm's disease
patients during the first year following diagnosis. Two hundred and thirty two patients
13
were diagnosed with Crohn's disease from 1990 - 1993, and rep.tesented a population-
based cohort in southeast Norway. Two hundred and twenty two of these patients were
followed prospectively for a mean of 16.2 months (range: 12-23 months). Relapse was
defined as a change in the clinical status of the patient that entailed more aggressive
medical treatment or surgery, whereas remission was defined as recdvery from the initial
treatment without clinical relapse until the end of follow-up.
The cumulative relapse rate between the time of diagnosis and 12 months follow-
up was 47 percent. Of those who did not have sustained remission during follow-up, 23
percent had greater than two relapses with 10 percent experiencing a chronic relapsing
course (> 5 relapses).
No differences were noted in the relapse rate based on disease location (colonic
only, small bowel only or small and large bowel disease), gender (p= 0.912), duration of
symptoms prior to diagnosis (p=0.834), or age «/= 50 years, >50 years, p=0.878). Risk
of surgery was not related to age, however patients with small bowel involvement only
had a higher risk of surgery compared to those with colon only disease (p=0.021). No
difference in rate of relapse or surgery was noted between smokers and non-smokers.
The strong points of this study are its relatively large sample size, uniform
criterion for diagnosis and therapy, low drop out rate (10 patients), prospective design
and population-based recruitment. The major weakness is its outcome variable of relapse
and that many relapses may have gone undetected if the patients did not present
14
themselves for evaluation. Again, the study is predominantly adul.t based. Unfortunately
the authors did not report on the number of pediatric patients included in the study, but it
was likely low as the median age was 30 years, interquartile range 22.5-47.5 (47).
Furthermore, the authors did not evaluate the relationship between disease activity at
diagnosis and relapse rate. The ability to extrapolate this informatiob to current practices
I
is limited since immunosuppressants including azathioprine were not used as
maintenance therapy in this study.
In a fifth study, Griffiths et al (48) reported on the two-year clinical course of a
prospectively compiled cohort of 100 consecutive, pre-pubertal patients with newly
diagnosed Crohn's disease from 1980 - 1988 in Toronto, Canada. Disease severity was
assessed during each year as; quiescent (no gastrointestinal or extraintestinal symptoms
reported; normal complete blood count and erythrocyte sedimentation rate), mild (some
symptoms but not needing prednisone treatment), moderate (intermittent symptomatic
exacerbations warranting prednisone or nutritional therapy) and severe (chronic
unremitting symptoms warranting prednisone or alternate treatment). Influence of
disease severity on linear growth velocity was also assessed.
Fourteen patients had quiescent, 54 mild, 23 moderate and 9 severe disease
activity during the first year following diagnosis. Similarly, 23 patients had quiescent, 42
mild, 25 moderate, and 9 severe disease activity during the second year following
diagnosis. Disease severity was determined to be a significant factor influencing growth
velocity during both the first and second years following diagnosis (p<0.01).
15
The strengths of this study include the relatively largt1: f sample size, uniform
diagnostic and outcome criterion, low-drop out rate (1 patient) and evidence that it
represented a population based sample. It was unique to the other studies in that a
pediatric cohort was assembled. While it clear:ly described the clinical course of
pediatric-onset Crohn's disease in the pre-immunosuppressant era, tlie results may not be
I
readily extrapolated to the present day. Furthermore, the study was not designed to
evaluate factors predictive of disease severity.
16
1.3.2 Morbidity
While inflammatory bowel disease has a low mortality rate (though some
investigators have reported it to be higher than that of the general population (49» the
chronic nature of this disease can result in significant morbidity (5,0). The morbidity
~
results from complications of the disease and/or therapy.
Complications of Crohn's disease include the development of arthritis/arthralgias
in 15 percent of patients (51), cutaneous manifestations (erythema nodosum, pyroderma
gangrenosum) (52), acute uveitis (51 ;52), urinary stones (53) and hypercoagulability with
development of deep vein thrombosis, pulmonary emboli and cerebrovascular disease
(54). Decreased bone mineral density is also a recognized complication of Crohn's
disease with osteopenic levels present in 25 percent of newly diagnosed children with
Crohn's disease (55;56).
Crohn's disease is associated with an increased risk for colorectal cancer (57;58).
In addition, Bernstein et al (58) in a population-based study demonstrated an increased
incidence rates ratio for carcinoma of the small bowel in Crolm's disease patients (17.4;
95% CI, 4.16-72.9). There is conflicting data as to whether Crohn's disease is associated
with an increased risk of lymphoma (59). Bernstein et al (58) calculated an increased
rates ratio for lymphoma in males with Crolm's disease (3.63; 95% CI, 1.53-8.62). In
contrast, a more recent cohort study from the United Kingdom of 6605 patients with
Crohn's disease followed for 3.7+/-2.4 years did not show an increased risk for
lymphoma (60), though follow-up may have been too short to adequately assess this.
17
Additionally, two unique aspects of childhood Crohn's dif)ease may increase the
risk for morbidity in pediatric patients. First, the need for children and young adolescents
to rapidly accrue lean body mass for growth and development makes them particularly
vulnerable to the adverse nutritional consequenGes of chronic inflammation (61).
Malnutrition and growth impairment are frequently observed problems of childhood
Crohn's disease (48;62). Second, development of Crohn's disease at an early age carries
the fundamental implication of a long life ahead with an increased risk of long-term
complications (63).
Crohn's disease is also associated with significant financial costs, both directly
from medical and surgical therapies and indirectly through lost days of work. In 1999,
Silverstein et al (50) estimated the lifetime costs of medical therapy for a representative
patient with Crohn's disease to be US$ 125 404 using mean charges and US$ 39 906
using median charges.
As illustrated in Table 1.3, the therapies used in Crolm's disease are also
associated with significant adverse effects that may further add to the morbidity
experienced by Crohn's disease patients. The need for surgical intervention is also high,
with up to 80 percent of patients requiring surgical resection within the first three years
following diagnosis (64). Unfortunately, recurrence is common, with greater than 80
percent having endoscopic recurrence and more than one third experiencing symptomatic
recurrence within three years following resection (65). As a result many patients require
multiple operations with the associated complications an.d morbidity.
18
Table 1.3 Side-Effect Profile of Crohn's Disease Therapies
Side-Effect Profile
- - -------
Sulphasalazine
5-ASA
Antibiotics
Oral prednisone
Azathioprine/6-mp
(adjunctive to steroids)
Methotrexate
(adjunctive to steroids)
Nausea, vomiting, headaches, mild hemolysis, fever,
Stevens-Johnson syndrome, pulmonary fibrosis,
hepatotoxicity, agranulpcytosis, reversible impairment of
male fertility, exacerbation of colitic 'ymptoms, reduced
folate absorption ~
f
Fever, rash, exacerbation of colitic ymptoms, acute
pancreatitis
Nausea, vomiting, increased antimicrobial resistance
Acne, moon facies, hirsutism, cutaneous striae,
pseudotwnOf cerebri, steroid psychosis, proximal
myopathy, hypercalcuria, aseptic necrosis of femoral head,
osteopenia, growth delay, cataracts, hyperglycemia,
Addisonian crisis
Fever, pancreatItIs, nausea, V0l11ltmg, leukopenia,
thrombocytopenia, infection, hepatitis
Nausea, increased liver enzymes, impaired folate
metabolism, hypersensitivity pneumonitis
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1.4 THERAPY
1.4.1 Therapeutic Goals
At present there is no cure for Crolm's disease. As such, the goals of treatment
are to induce remission and subsequently maintain remission while minimizing
therapeutic complications and optimizing patient quality of life (66;t7). A wide variety
of medications are currently available with proven efficacy fOl induction and/or
maintenance of clinical remission (Tables 1.4 and 1.5). In general, these include
medications with anti-inflammatory properties, immunosuppressant properties and those
with both.
1.4.2 Current Treatment Paradigms
The variable natural history of Crolm's disease and the possibility of spontaneous
remissions and exacerbations make treatment selection difficult. Initial treatment
algorithms currently advocate a 'step-up' approach (Figure 1.2), basing the selection of
therapy primarily on disease activity. Less potent medications such as antibiotics and 5-
aminosalicylates are used for milder disease activity. More potent medications such as
systemic corticosteroids and enteral nutrition are reserved for moderate-severe disease
activity. Immunomodulating pharmacotherapy with azathioprine, 6-mercaptupurine (6-
mp), methotrexate or tacrolimus (FK506) are introduced later for intractable or relapsing
symptoms. Surgical intervention is used for those patients with medically refractory
disease or complications such as fistulization and/or stenosis.
More recently, novel medications with specificity for intermediate metabolites in
the inflanm1atory cascade have been developed, and include infliximab (an anti-
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Table 1.4
j'
Induction of Remission in Crohn's Disease (11;68;69)
5-ASA
Antibiotics
Oral prednisone
Azathioprine/6-mp
(adjunctive to steroids)
Methotrexate
(adjunctive to steroids)
Enteral Nutrition
Placebo
4 g/d
1-2mg/kg (60mg)
AZA 2-3 mg/kg/day
6-mp 1.5mg/kg/day
25 mg/wk im/sc
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43
, 40-50
60-78
36-65
39-54
50-75%
8-50
Table 1.5 Maintenance of Remission in Crohn's Disease (68-~.O)
5-ASA
Oral prednisone
Azathioprine/6-mp
Methotrexate
(methotrexate responders)
Placebo
1.5 - 4 g/d
2.5(1.5) mg/kg/day
15 mg/wk
22
25-69
.No Benefit
40-85
j 39-54
35-64
Severe
Infliximab
Surgery
Bowel rest
Moderate
Mild
t Prednisone 4CorticosteroidsBudesonide
Antibiotics
Aminosalicylates
AZA/6-MP/
MTX
Adapted from Hanauer. http://wwwmedscape.com
Figure 1.2 Conventional 'Bottom-Up' Therapeutic Paradigm
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TNF-alpha chimeric antibody) and etanercept (a dimeric fusion pr~ttein consisting of the
extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis
factor receptor (TNFR) linked to the Fc portion of human IgGl). Such therapies are
currently reserved for patients who have had an uns~tisfactory resp0J)se to conventional
immunosuppressants.
1.4.3 Early Introduction of Immunosuppressive Therapy?
With increased understanding of the pathogenesis of Crohn's disease, researchers
hope to improve its clinical course and decrease morbidity. While several studies (70-74)
have established a benefit for immunosuppressive agents in inducing and maintaining
remission in steroid-dependent and refractory Crohn's disease, more recently researchers
have sought to study the effect of the early introduction of immunosuppressants on
clinical course.
Markowitz et al (75) in a double-blinded trial, prospectively randomized newly
diagnosed pediatric-onset Crohn's disease patients who were to be started on systemic
corticosteroids to receive either concomitant therapy with 6-mercaptopurine (n=27) or
placebo (n=28). Moderate-severe disease was defined as partial Harvey-Bradshaw (HB)
index >/=5. Remission was defined as 2 successive monthly total HB scores of <3, and
relapse as 2 successive scores (obtained no closer than 1 week apart) of>/=4.
Remission was induced in 89 percent of patients in both groups. Of interest, over
a follow-up period of up to 548 days, 9 percent of remitters in the 6-mercaptopurine
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group relapsed as compared to 47 percent of controls (p:,0.007) (Figure 1.3).
Furthermore, in the 6-mercaptopurine group, the duration of steroid use was shorter
(p<O.OOI) and the cumulative steroid dose lower at 6,12 and 18 months (p<O.OI).
In a separate study, Kugathasan et al enrolled fifteen childr~n (6-18 years) with
medically-refractory Crolm's disease into a prospective open-:Iabel tria~ to receive a single
5mg/kg dose of infliximab (76). Medically-refractory disease was defined as the inability
to tolerate steroid taper, disease activity measured on the Pediatric Crohn's Disease
Activity Index (PCDAl) as a score >/=30 and no improvements despite the use of
immunomodulatory therapy (6-mp, methotrexate and/or cyclosporine A) for >/=4
months. Clinical relapse was defined as the need for additional medical or surgical
therapy to treat the Crohn's and an increase in the PCDAl score by at least 15 points.
By week four following infliximab administration, fourteen patients (93.3%) had
improved (decrease in PCDAl </=25 points). Interestingly, of the responders, six
(42.9%) had early disease (defined as disease duration <2 years from the time of
diagnosis), and eight (57.1 %) had late disease. Three (50%) of patients with early disease
maintained clinical response through the 12-month trial period compared to none of the
eight children with late disease.
There are a number of concerns with both studies. In the study by Markowitz et
aI, ten patients (15.4%) that were originally randomized were not included in the analysis
(7 changed their minds before therapy was initiated; 2 did not keep sufficient follow-up
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Figure 1.3 Effect of Early Introduction of Azathioprine in Childhood Crohn's Disease (62)
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appointments; I was withdrawn for non-compliance to therapy)( In addition, only 78
percent (21/27) of patients in the 6-mp group and 39 percent (11/28) of controls
completed the full 18-month trial. The primary reason for withdrawal was treatment
failure (3 6-mp subjects, 15 controls). Both of these factors raise concerns that the results
may contain bias secondary to the high withdrawal rates. Furthermore, the study by
I
Kugathasan et al was under-powered (15 patients) preventing gerieralization of the
observations. It was also an open-label study without a control group for comparison.
For these reasons the study is particularly vulnerable to bias.
These issues not withstanding, both studies provide preliminary evidence that the
use of immunomodulatory medication in patients with moderate-severe, recent-onset
Crohn's disease may prolong the duration of clinical remission. The reason for this
observation is not known, though data does exist to indicate that the cytokine profile may
differ in recent-onset and long-standing Crohn's disease (77). Furthermore, Kugathasan
et al demonstrated that mucosal T cells isolated from children with early Crohn's disease
were more susceptible to immunomodualtion with IL-I2 then were those from children
with late Crohn's disease (78). Similarly, GiaImini demonstrated that the early use of
methotrexate resulted in improved clinical outcome and decreased need for steroids in
patients with rheumatoid arthritis (79). All of this data suggests that patients with
Crohn's disease (and other immune-mediated diseases) may respond better to early use of
immunomodulatory therapies and that the response may be attenuated when used in long-
standing disease.
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1.4.4 Future Treatment Paradigms
The previous data support the concept that the early introduction of
immunosuppressants in Crolm's disease can alter its clinical course by prolonging the
duration of remission. This data, along with the int~?duction of new medications such as
infliximab, a chimeric monoclonal anti-TNFalpha antibody, has led many to re-think the
I
current 'step-up' treatment paradigm. Researchers have proposed ,that a 'step down'
therapeutic paradigm (Figure 1.4) with the early introduction of immunosuppressants
may lead to better clinical outcomes and decreased morbidity.
A major concern with such an approach is that many patients with Crohn's disease
who would have a relatively mild clinical course would be exposed to the potential
adverse effects of immunomodulator therapy. The issue then is to identify those patients
with Crohn's disease that would have a more severe clinical course and therefore may
have a more favourable risk:benefit ratio for the early institution of immunomodulator
therapy.
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Late
5-ASAIAntibiotics
Figure 1.4 Proposed 'Top Down' Therapeutic Paradigm
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Adapted from Hanauer.
http://wwwmedscapecom
1.5 PROGNOSTIC INDICATORS OF DISEASE SEVERITY
As previously cited in Section 1.2.1, a number of studies (43-46) have attempted
to identify prognostic factors in Crolm's disease. However, no factor at diagnosis was
consistently found to be prognostic of future disease'eutcome.
Truelove et al (43) found that female gender was associated with a higher
incidence of mortality over a five-year period as compared to males (4.6% versus 0.6%).
Unfortunately, no statistical analysis was performed. Age was not found to be associated
with mortality.
Munkholm et al (44) determined that disease activity in anyone year was related
to the disease activity in subsequent years. They did not however find any relationship
between disease course and such variables as gender, age, year of diagnosis, localization
of Crohn's disease or histological evidence of disease.
Faubion et al (45) found no relationship between age, gender, interval to
corticosteroid therapy from diagnosis or disease extent to the clinical course over a one
year period from initial use of corticosteroids. Furthermore, Mourn et al (46) determined
that relapse rate was not associated with age, gender, duration of symptoms prior to
diagnosis or disease location.
Unfortunately all of these studies had significant limitations. First, all were
reported on cohorts assembled prior to 1994 when treatment with immunosuppressives
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was uncommon. This limits their applicability to present day pop~1ations. Second, as all
the cohorts were predominantly adult based, the data may not be generalizable to
childhood-onset Crohn's disease. Third, the outcome variables of remission and relapse
were not standardized therefore limiting the ability"to make comP1risons between the
4
studies. Furthermore, while the Munkholm (44) study did show a ~elationship between
disease activity in one year with that in subsequent years, no stud/ has evaluated the
ability of markers of disease activity, including ESR and albumin, to predict disease
severity.
MEDLINE searches failed to identify any study analyzing for the presence of
prognostic factors in pediatric-onset Crolm's disease. Of interest, however, Hyams et al
(80) published on the clinical course of 171 pediatric patients (age 1.5-17.7 years) with
newly diagnosed ulcerative colitis retrospectively compiled from two North American
centers from 1975-1994. Forty-three percent had mild disease at presentation «/= 4
stools/day, the presence of blood in the stool less than daily, and no systemic symptoms
such as fever or weight loss). Fifty-seven percent experienced moderate/severe disease
(>/= 5 stools/day, and the daily presence of blood, with or without the presence of
systemic symptoms). Of note, mild disease activity was associated with a significantly
lower risk of colectomy (p<0.03) compared to those with moderate/severe disease, at
one-year (1 % versus 9%) and five-year (8% versus 26%) follow-up. This data indicates
that in ulcerative colitis, disease activity at diagnosis is predictive of disease severity, as
defined by need for colectomy.
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Chapter 2 - RATIONALE AND OBJECTIVES
2.1 STUDY RATIONALE
I'
As discussed, few studies have attempted to ascertain epidemiological trends or to
characterize the natural history of pediatric Crohn's. disease. A well designed study in
which baseline characteristics are correlated with subsequent disease pattern and
I
outcomes would help optimize initial treatment recommendations for individual patients.
2.2 POST-HOC ANALYSIS
Prior to conducting a study to identify baseline variables of disease severity, it
was decided to assess the relationship between disease severity from year to year in
pediatric-onset disease. A cohort of patients with Crohn's disease had previously been
assembled at the Hospital for Sick Children, Toronto, Canada to assess the clinical course
and growth of Crohn's disease in pre-pubertal children (62). For this thesis, data
collected for that study was used to perform a post-hoc analysis with the primary purpose
to evaluate the relationship between disease severity during subsequent years.
One hundred sixty-six consecutive Crohn's disease patients (l08 males) at TaImer
stage I (n=146) and Tanner stage II (n=17) of pubertal development were followed at the
Hospital for Sick Children, Inflammatory Bowel Disease Clinic, from January 1990 -
December 1999. These patients were identified using a prospectively maintained
database of all patients with inflammatory bowel disease seen at the Inflammatory Bowel
Disease clinic at the Hospital for Sick Children, Toronto since 1980. At each year for up
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to five years of follow-up, patients were classified as having fither quiescent, mild,
moderate or severe disease Crable 2.1) (48).
This annual severity assessment was feasible because of c.ustomary follow-up
practices in the Inflammatory Bowel Disease clinic. At follow-up visits standardized
forms, originally designed to allow regular computation of the Pediatric Crohn's Disease
Activity Index (PCDAI), are routinely used to record gastrointestinal symptoms
(abdominal pain, diarrhea, weight loss, anorexia, etc.) and extra-intestinal manifestations
and treatments. Complete blood count, serum albumin and ESR are regularly measured.
Prior to analysis, attempts were made to ascertain if this cohort represented a
population-based study. In the Toronto Census Metropolitan Area, no pediatric
gastroenterologist practiced outside of the Hospital for Sick Children prior to 1997 and
general pediatricians did not independently manage such patients. In 1997, a survey was
mailed out to all practicing adult gastroenterologist in the Toronto Census Metropolitan
Area (Appendix A) who were listed in the 1997 Membership Directory of the Canadian
Association of Gastroenterology (81). The gastroenterologists were asked to provide data
on the number of pediatric patients with inflammatory bowel disease that they followed
independently of the Hospital for Sick Children for the period of 1980-1990 and 1991-
1997. The response rate was 58 percent. Of those gastroenterologists who saw patients
less than 15 years of age, none saw more than two patients. If the gastroenterologists
who responded to the questionnaire are representative of others in the community, these
findings would indicate that the inflammatory bowel disease database captured 95 percent
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Table 2.1
Severity
Quiescent
Mild
Moderate
Global Assessment of Disease Severity
Definition
No intestinal (diarrhea, blee9ing, abdominal pain) or
extraintestinal symptoms reported; normal <iBC and ESR
Some symptoms, but not requiring corticosteroid, enteral
nutrition or surgical treatment
Symptomatic exacerbations warranting corticosteroid, enteral
(Exacerbations
with remissions)
Severe
(Chronically active)
nutrition or surgical treatment alternating with the occurrence
of symptom free intervals of at least one months duration,
excluding when the patient received corticosteroid, enteral
nutrition or surgical therapy
Chronic unremitting symptoms warranting corticosteroid,
enteral nutrition or surgical therapy; or the presence of
corticosteroids or enteral nutrition at least 50% of the time and
recurrence of symptoms when corticosteroids or enteral
nutrition is stopped
34
of children less than 15 years of age at diagnosis in the Toron¥, Census Metropolitan
Area, thus closely approximating a population based cohort. As such, only those patients
who resided in the Toronto Census Metropolitan Area and were less than 15 years of age
at diagnosis (n=83) were included in the post-hoc aniJ.lysis of this cohort.
I
Chi-square analysis and Spearman correlation were performed to assess the
relationship between disease severity in anyone year with disease severity in subsequent
years.
Of these 83 patients the mean age at diagnosis was 10.8 +/- 2.0 years. Twenty-
three (27.7%) were female. Twenty-eight (33.7%) had disease limited to the small bowel
only, 40 (48.2%) had disease involving both the large and small bowel and 15 (18.1%)
had isolated colonic disease. Systemic corticosteroids were used as the initial therapy in
62.7 percent of patients and 71.1 percent of patients required at least one course of
systemic corticosteroids during the first year following diagnosis.
During the first year following diagnosis, 18 (21.7%) patients had quiescent
disease, 25 (30.1 %) mild disease, 23 (27.7%) moderate (intermittent exacerbations) and
17 (20.5%) had severe (chronically active) disease. As demonstrated in Figure 2.1, the
proportion of patients in each category was similar over each year of follow-up.
As illustrated in Figure 2.2 and Table 2.2, disease severity in anyone year was
related to that observed in the preceding years. In other words, patients with
35
.......
=QJ
~
~
QJ
~
100
90
80
70
60
50
40
30
20
10
o '(((((((I I ( ( ( ( ( ( ( , I ( ( ( ( ( ( ( , Ie ( ( ( ( ( ( J [ ( { ( / ( ( /1
Year 1 Year 2 Year 3 Year 4 Year 5
Time
c:=:J Severe
~Moderate
rnm Mild
EZZZZJ Quiescent
Figure 2.1 Percentage of Patients with Quiescent, Mild, Moderate and Severe Disease During Each Year
After Diagnosis.
36
Years after Diagnosis
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Figure 2.2 One-year probabilities of moderate/severe disease (-) or quiescent/mild
disease (-) the following year, provided: moderate/severe disease the previous year
(2.2a) or quiescent/mild disease the previous year (2.2b).
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Table 2.2 Post-Hoc Analysis: Relationship between disease severity in anyone year with subsequent years
------- - -
Initial Subsequent n p r Spearman p
Year
_.'....n_ .._ Year ~_..- ...._._---...._.- -------- - _.__._------~-
2 83 . 27.82 0.0282 0.4334 <0.0001
3 78 18.67 0.0042 0.2476 0.0289
4 70 28.78 <0.0007 0.2950 0.0132
5 53 32.60 0.0002 0.4626 0.0005
Overall 83 37.09 <0.0001 0.5447 <0.0001
78 44.78 <0.0001 0.5112 <0.0001
4 70 21.57 0.0103 0.2979 0.0123
5 53 14.88 0.0943 0.4047 0.0027
Overall 83 48.37 <0.0001 0.5835 <0.0001
4 70 43.11 <0.0001 0.5054 <0.0001
5 53 23.54 0.0051 0.4194 0.0018
Overall 78 61.15 <0.0001 0.5818 <0.0001
5 53 45.16 <0.0001 0.6039 <0.0001
Over all 70 43.69 <0.0001 0.4311 0.0002
Overall 53 33.03 0.0001 0.4~63 ~ 0.0002
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moderate/severe disease in one year were more likely to have moderat'e/severe disease in
subsequent years. The converse was also true, in that those with quiescent/mild disease
were more likely to continue to have quiescent/mild disease in the subsequent year.
Fifty-eight percent of patients with moderate/severe disease over the first year following
diagnosis were more likely to continue to have a moderate/severe diseas~ over the second
year. Likewise, 62 percent of patients with quiescent/mild disease over tHe first year after
diagnosis continued to have a quiescent/mild disease during the second year.
The data from the post-hoc analysis clearly demonstrated a relationship between
disease severity in consecutive years, which was similar to that described by Munkholm
et al (44). However, it is recognized that there does exist significant variability in disease
severity that is not explained by prior disease pattern. With this data suggesting a
relationship between disease severity from year to year, and the data from Hyams et al
(80) demonstrating that disease activity at diagnosis is predictive of colectomy in
ulcerative colitis, it is natural to pose the following question. Is disease activity at
diagnosis predictive of future disease severity in pediatric-onset Crohn's disease?
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2.3 STUDY HYPOTHESIS
Patients with high disease activity at diagnosis are more likely to have a more
severe disease course over the first year following diagnosis.
2.4 STUDY OBJECTIVES
1) To determine if disease activity at diagnosis is predictive of severity of pediatric-
onset Crohn's disease during the first year following diagnosis.
2) To identify baseline factors predictive of disease severity.
3) To document the clinical course of pediatric Crohn's disease for an inception cohort
during the first year following diagnosis.
4) To assess the influence of early immunosuppressive therapy on disease severity.
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Chapter 3 - STUDY METHODOLOGY
3.1 STUDY DESIGN
3.1.1 Study Design
An inception cohort composed of pediatric patients with newly diagnosed Crolm's
disease was assembled at the inflammatory bowel disease clinic, Hospital for Sick
Children, Toronto. Recruitment was facilitated by the inflammatory bowel disease
database that has been prospectively maintained on all patients with inflammatory bowel
disease followed through the Hospital for Sick Children since 1980.
3.1.2 Study Population
The target population was children and adolescents at the time of their initial
diagnosis of Crohn's disease at the Hospital for Sick Children, Toronto. Patients were
prospectively recruited from July 1997 to May 2001. Follow-up continued for one year
following diagnosis, with the last follow-up occurring in May 2002.
3.1.3 Inclusion/Exclusion Criteria
Inclusion criteria:
1. A new diagnosis of Crohn' s disease (Appendix B); a diagnosis of Crohn's disease was
made if a potential case met at least two of the following criteria:
- clinical history of abdominal pain, weight loss, malaise, diarrhea, and/or rectal
bleeding for at least 2 months;
- endoscopic findings of mucosal cobblestoning, linear ulceration, skip areas, or
perianal disease;
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- radiological findings of stricture, fistula, mucosal cobble~roning,or ulceration;
- macroscopic appearance of bowel wall induration, mesenteric lymphadenopathy,
and "creeping fat" at laparotomy; or
- pathological findings of transmural inflamn1ation and/or epithelioid granulomas.
These criteria were identical to those used in previous studies4(21 ;82).
2. Age < 17 years.
3. Availability of required baseline information.
4. Informed consent obtained for prospectively recruited subjects.
Exclusion criteria:
1. Patients with ulcerative colitis; the diagnostic criteria for ulcerative colitis was the
presence of at least two of the following four criteria: (21 ;82)
- clinical history of diarrhea, stools containing blood and pus, or both
- macroscopic appearance at endoscopy, with continuous mucosal inflammation
affecting the rectum in continuity with some or all of the colon with granulated
friable mucosa or ulcerations, or both
- histological signs of inflammation
- no suspicion of Crolm's disease on small-bowel roentgenography, ileoscopy, or
biopsy
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2. Patients with indeterminate colitis; a diagnosis of indeterminate colitis was made if
endoscopy and histopathology were either inconclusive or divergent with regard to the
diagnosis ofCrohn's disease or ulcerative colitis (21}.
3. Patients with any co-morbid condition, including but not limited to hepatic, renal,
cardiovascular, neurological, or psychiatric diseases that were determined to be of clinical
relevance for the purposes of this thesis. Specifically, any co-morbid illness that had a
significant impact on disease severity would be excluded. (Of note, no patients were
excluded for this reason)
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3.2 STUDY OUTLINE
A one-year follow-up study was conducted as outlined in Figure 3.1.
Baseline characteristics measured at diagnosis included: age; gender; duration of
symptoms; date of diagnosis; family history of IBD; current medications; height; weight;
signs on physical examination; Tanner pubertal stage; stool cultures; albumin; ESR;
platelet count; hemoglobin; radiological findings; endoscopy findings; and pathology.
Pediatric Crolm's Disease Activity Index (PCDAI) scores were calculated on all patients.
Crohn's Disease Endoscopic Index of Severity (CDEIS) scores were collected on patients
diagnosed between August 2000 and May 2001.
Follow-up data was collected at six weeks, six months and one year after initial
diagnosis. Data was also collected during intermittent hospitalizations. Data collected
included: frequency and consistency of bowel movements; presence of blood and mucus
in stools; abdominal pain; current medications; growth parameters; Tanner stage;
albumin; ESR; platelet count; hemoglobin; and PCDAI scores. Response to initial
therapy was collected only at 6 weeks. IMPACT (quality of life) scores were collected at
6 and 12 months in those patients >/=10 years old from August 2000 to May 2001.
Follow-up data was collected where possible in the GI outpatient clinic and
during hospitalizations. For patients unable to attend follow-up clinics, arrangements
were made for the patients' family physician or pediatrician to collect the required
information.
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3.3 MEASUREMENT/VARIABLES ('
3.3.1 Index Measurements
Disease activity for Crohn's disease was measured using the Pediatric Crolm's
Disease Activity Index (PCDAl) (Appendix C) .(83). The PCDAI is a multi-item
instrument that was specifically developed as an objective measure 6f disease activity in
I
pediatric patients with Crohn's disease (83). The PCDAI consists of 11 criteria, assessing
three main categories: symptoms, laboratory markers of inflammation, and physical
examination findings including an evaluation of growth velocity. Scores range from 0 -
100 in increments of2.5. Higher scores reflect more active disease. A PCDAI value >30
correlates with moderate and severe disease activity and a value <15 with inactive disease
(84). The PCDAI has been validated and has been demonstrated to be more feasible and
to more accurately reflect disease activity in children than does the adult patient derived
Crohn's Disease Activity Index (CDAl) (84). More recently, it has been demonstrated
that the PCDAI is responsive to short-term changes in disease activity (85).
For patients recruited between August 2000 and May 2001, the CDEIS was
collected at the initial colonoscopy (if performed prior initiation of therapy) to grade the
macroscopic severity of disease. The score is based on the presence of deep or
superficial ulceration, the proportion of ulcerated surface and the presence of ulcerated or
non-ulcerated stenosis in five separate regions (rectum, sigmoid and left colon, transverse
colon, right colon and ileum) (86). Scores range from 0 - 44 with higher scores reflecting
more severe involvement. The CDElS has been validated for use in adults by a
prospective multi-center study (86). It is reproducible and responsive (86).
46
Unfortunately, correlation with clinical and laboratory indexes Gmcluding hemoglobin,
ESR, stool frequency, CDAI - Crohn's Disease Activity Index) and with prognosis
appears to be poor (86-90).
For each colonoscopy, two independent evaluations wer~ completed. The
consultant gastroenterologist or gastroenterology fellow performing the colonoscopy
completed one CDEIS assessment. Another examiner (JC) performed a second
assessment of the CDEIS either at the time of the colonoscopy or afterwards by
reviewing videotapes. In addition, both reviewers completed a 10cm visual analog scale
(VAS) to indicate their assessment of the endoscopic severity. While the CDEIS has not
been specifically validated for use in pediatric patients, as the endoscopic findings of
Crohn's disease has not been shown to be appreciably different between children and
adults, it was judged that use of this index was acceptable for purposes of this thesis.
Clinical response to initial therapy was assessed at the 6-week follow-up visit.
Clinical response was classified into 1 of 3 categories (45).
The categories were:
1. Complete remission: defined as total regression of clinical symptoms «/= 2
bowel movements/day; no blood, pus, or mucus in feces; and no abdominal
pain, fever, weight loss or extraintestinal symptoms.
2. Partial clinical remission: defined as regression of clinical symptoms «/= 4
stools/day; blood, pus, mucus in feces; or abdominal pain; or all four less than
daily and no systemic symptoms, such as fever or weight loss).
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3. No response: defined as no regression of clinical symptpms.
Quality of life was assessed at the 6 and 12 month visits (between August 2000
and May 2002) by patient completion of the IMPACT questiOlmaire (91;92) (Appendix
D). The IMPACT questionnaire was developed and validated a~ a disease specific
t
measure of quality of life for use in pediatric patients (late childhood and adolescences)
with inflammatory bowel (91). It is a self-administered questionnaire composed of 33
questions encompassing six domains: bowel (6 concerns), body image (3 concerns),
functional/social impairment (11 concerns), emotional impairment (11 concerns),
tests/treatments (3 concerns), and systemic impairment (2 concerns). A 10cm visual
analog scale is employed to capture the response for each question. Each component is
equally weighted and composite scores range from 0 - 231 with higher scores reflecting a
better quality of life.
3.3.2 Outcome Variable - Definition
The primary outcome variable of disease severity was determined by a physicians'
global assessment of disease course over the preceding year, excluding the immediate
two months after therapy was initiated, as defined in TallIe 2.1. Versions of this
classification system had been used successfully in previous studies (48;80;91). Disease
severity was sub-divided into four groups; quiescent, mild, moderate (exacerbations with
remissions) and severe (chronically active disease). In general terms, categorization of
disease severity was based upon symptom pattern (duration and severity of symptoms)
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and the potency of therapy required (specifically the need for prolonged or repeated
systemic corticosteroids, enteral nutrition or surgical resection).
Prior to proceeding, it is important to differentiate between the explanatory
variable of disease activity as measured by PCDAI and the primary butcome variable of
I
disease severity. Disease activity is a reflection of inflammation at one point in time. In
contrast, disease severity is a multi-dimensional concept. It is often derived from the
physician and/or patient making a composite assessment of multiple attributes including,
disease activity, sequelae of disease, and its treatment and health states (i.e. perceived
quality of life) over a period of time. Prior to study commencement, no validated
measure of disease severity in pediatrics Crolm's disease had been published. For
purposes of this study, the assessment of disease severity was based on the physicians'
global assessment of severity, as defined in Table 2.1.
3.3.3 Outcome Variable - Validation
In the absence of a previously validated measurement of disease severity in
pediatric-onset Crohn's disease, this thesis was designed to concurrently validate the
outcome measure of disease severity as defined in Table 2.1. As previously discussed,
validated outcome variables are an essential component of clinical studies.
Outcome measures should be demonstrated to adhere to four properties:
feasibility, reliability, validity and responsiveness (93).
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1) Feasibility refers to the ease in which a measurement c~h be made.
2) Reliability of a measurement refers to its reproducibility (93). That is, the
measurement of an unchanged entity on different occasions by the same
observer (intra-rater reliability) or by different o~servers (inter-rater
reliability) produce similar results.
3) Validity is concerned with how well an instrument measures what it was
designed to measure (93). A number of approaches are employed to assess
validity, but in the absence of a clearly defined external criterion ('gold
standard') the process of construct validation is necessary (91 ;93;94). In
construct validation, hypotheses are developed a priori based on how it is felt
the measure should act. The measure is then tested against these hypotheses
to determine if it is acting in the predicted maimer.
4) Responsiveness refers to the ability of a measure to detect change in an entity
over time.
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3.4 SAMPLE SIZE
As this study was designed to enable construction of a multivariate regression
model to determine the relationship between 5 to 9 baseline variables with disease
outcome (moderate/severe disease), a minimum of 4~ patients (cases) was required. This
was based on the need for 5-10 patients with moderate/severe aisease per baseline
variable analyzed (94;95).
3.5 ANALYSIS
3.5.1 Variables
Explanatory variables
Baseline variables to be evaluated as prognostic indicators of disease severity
included categorical variables: gender, disease location, initial hospitalization, initial
systemic corticosteroid use and response to initial therapy at six weeks; and continuous
variables: albumin, ESR, CDElS (patients recruited from August 2000 to May 2001) and
PCDAl score.
The laboratory variables (ESR, albumin), the index scores (PCDAl, CDEIS) and
the categorical variables (initial hospitalization, initial systemic corticosteroid use,
response to initial therapy) were pre-selected for analysis as they were felt to be surrogate
markers of disease activity. These were also variables that could be objectively measured
and easily collected in both a research and clinical setting. Disease location and gender
were also pre-selected for inclusion as they were felt to be possible important
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demographic factors affecting disease severity. Age was not analo/zed due to the narrow
age range of patients that were recruited. Explanatory variables were limited in the
primary analysis to those listed above, as these variables were felt to likely be clinically
relevant (as opposed to being solely statistically'felevant) and thus more applicable
physiologically for inclusion into a logistic regression model (96). 4Furthermore, it was
pre-determined to limit the number of explanatory variables in the primary analysis to
reduce the chance of type I errors. This not withstanding, secondary analysis was
performed on several other variables (baseline platelets, duration of symptoms prior to
diagnosis and positive family history ofIBD) to identify other possible predictive factors.
Outcome Variable
The primary outcome variable of interest is disease severity (quiescent, mild,
moderate - exacerbations alternating with remission, and severe - chronically active
disease) as defined previously in Table 2.1. The four categories of the primary outcome
variable were condensed into two groups prior to analysis. Quiescent disease was
grouped together with mild disease and moderate (exacerbations with remissions) disease
was grouped together with severe (chronically active) disease. The contraction of the
outcome variables into two groups (mild/quiescent and moderate/severe) was justified on
the basis that it was clinically more relevant to identify those patients with
moderate/severe disease from those with quiescent/mild disease, as it is collectively the
moderate/severe disease group that received the more aggressive treatments and therefore
may arguably have a more favourable risk:benefit ratio for the early introduction of
immuno-modulators.
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Assessment of Liner Growth (.'
Height was measured at each visit using a wall-mounted stadiometer. Heights
were converted to z-scores with data sets used to construct the Centers for Disease
Control and Prevention (CDC) 2000 growth charts (.~7). A z-score is the deviation of the
height for an individual from the mean height of the reference popufation divided by the
standard deviation for the reference population.
3.5.2 Validation of Primary Outcome Variable
Validation of the primary outcome variable was conducted by demonstrating
adherence to the properties of feasibility, reliability and validity:
Feasibility: Testing was conducted by evaluating the ease with which the
observers were able to grade disease severity in the cases. The presence of incomplete
assessments was also recorded.
Reliability: Evaluation of both inter-rater and intra-rater reliability of the outcome
variable was performed. Intra-rater reliability was assessed by having one examiner (JC)
assign the disease severity grade at two separate times, separated by several months. This
was possible as the outcome variable of disease severity was retrospectively assigned,
allowing the examiner (JC) to review the records and re-assign the grade while blinded to
his original assessment. Inter-rater reliability was assessed by having two examiners (JC,
AG) independently assign the disease severity grade to each case.
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Validity: Assessment was conducted by constructing h'ypothesis on disease
severity a priori, as outlined in Table 3.1. As disease severity is likely to be dependent
on many factors, hypothesis were constructed by choosing variables (duration of
hospitalization, number of hospitalizations, quality- of life (IMPACT scores), disease
4
activity over time (mean of peDAl scores measured at 6 and 12 months) and linear
I
growth) that were postulated to be correlates of disease severity. j Importantly, the
outcome measure of disease severity utilized in this study was defined independently of
the variables chosen for construct validation.
Responsiveness: The responsiveness of the outcome measure for disease severity
was not determined. As the outcome variable was designed to assess disease severity
over the one-year period examined in this study, it was not possible to test responsiveness
within the context of this thesis. To assess for responsiveness, it would have been
necessary to extend the study interval to two years. In the context of this thesis, failure to
demonstrate responsiveness of the outcome variable was not felt to be limiting, as this
property was not required for purposes of this study.
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Table 3.1 Construct Hypothesis for Validation of Primary OlJtcome Variable
Construct Hypothesis
1. Duration of hospitalization should be longer in patients with moderate/severe disease.
2. Number of hospitalizations should be higher in patients with mod~'rate/severedisease.
3. IMPACT scores should be lower in patients with moderate/severe disease.
4. Linear growth should be lower in patients with moderate/severe disease.
5. Mean PCDAI scores should be higher in patients with moderate/severe disease.
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Statistical Analyses3.5.3
I.'
Analyses were initially performed using the two-category (mild/quiescent and
moderate/severe) primary outcome variable, for reasons justified previously. A second
analysis was conducted with the primary outcome v.~riable divided into the four separate
categories (quiescent, mild, moderate, severe).
Univariate Analyses
To identify risk factors for moderate/severe disease, univariate analyses were
initially performed using the selected baseline variables. Fisher's exact test was used for
categorical variables and the unpaired Student's t-test for normally distributed continuous
variables. Mann Whitney U (MWU) test was used for continuous variables that were not
normally distributed. Testing for normality was performed. Data was evaluated for
kurtosis and skewness. Levene's test was used to examine for equality of variances. For
the four-category outcome variable, chi-square analyses were used for categorical
variables and ANOVA for continuous variables. Nonparametric tests were used if testing
failed to ensure the assumption of a normal distribution.
Mulitvariable logistic regression
Baseline characteristics found to be associated with poor outcome at a level of
significance </= 0.05 were entered into a multivariate logistic regression model. It was
decided to include gender into the multivariate model, even if non-significant by
univariate analysis, as it is an important demographic factor. A backward regression
model was developed to predict poor outcome (moderate/severe disease) at one-year
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follow-up. Risk factors were sequentially removed from the moddt based on two criteria:
the variable was not a statistically significant predictor of poor outcome at the p<0.05
level, and removal of the variable resulted in a reduction of the area under the receiver
operating characteristic (ROC) curve by <0.03. First level multiplicative interaction
4
terms were studied. Explanatory variables were assessed for multicollinearity in each
I
model. Possibility of a high multicollinearity problem was suggested if the correlation
coefficient was >/= 0.8 (98). Data was reviewed for the presence of standardized
residuals >2.58, 0.01 significance level. Models were evaluated using percent
concordance, Nagelkerke R2, and Hosmer and Lemeshow's goodness-of-fit test. The area
under the ROC curve, a commonly used measure of the predictive power of a statistical
model, was assessed.
Ordinal logistic regression analyses were used for the four-category outcome
variable.
Validation of outcome variable
Reliability: Kappa statistic was used to calculate both intra-rater and inter-rater
agreement for the outcome variable disease severity. Testing was performed for both the
contracted two-category form (quiescent/mild and moderate/severe) and for the four-
category form (quiescent, mild, moderate, and severe). Kappa statistic was selected as
the most appropriate test to use as the outcome variable was of the categorical ordinal
type (99). A kappa statistic >0.80 represents excellent agreement, 0.60 - 0.80 substantial
agreement, 0.40 - 0.60 moderate agreement and <0.40 poor to fair agreement (99;100).
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Validity: Testing of the construct hypothesis was perf9limed using univariate
analysis. Fisher's exact test was used for categorical variables and the unpaired Student's
t-test for normally distributed continuous variables. The Mann-Whitney U test was used
for continuous variables that were not normally. distributed. For the four-category
outcome variable, chi-square analyses were used for categorical vaiiables and ANOVA
I
for continuous variables. A strong correlation was defined as r>0.5, a moderate
correlation r>O.4 and a mild or weak correlation r>0.3. Analyses were conducted using
parametric techniques. Nonparametric tests were used if testing failed to ensure the
assumption of a normal distribution.
CDEIS agreement
Intra-class correlation (ICC) was used to evaluate agreement between the two
examiners for both the CDEIS and the visual analog scores (VAS). Inter-rater reliability
was analyzed using ICC Model 2 (repeated measures ANOVA) for single measurements,
with raters selected as the independent variable (99). As a general guideline, ICC >0.75
is indicative of good reliability and <0.75 of poor to moderate reliability. It has been
suggested, that the ICC should exceed 0.90 for clinical measurements (99). Pearson's
correlation was used to evaluate the correlation between CDEIS and visual analog scores
(VAS) for each observer.
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Data management
Data was stored in Microsoft Excel 97. All analyses were performed using the
statistical package SPSS 11.0 - 12.0 for windows and/or SAS Version 8.10 for windows.
Statistical significance was determined at a two-tail€d level of 0.05, Statistical support
was provided through consultation with statisticians at the Faculty of Medicine,
University of Toronto and the Research Institute, Hospital for Sick Children.
3.6 ETHICAL CONSIDERATIONS
Approval was obtained from the Research Ethics Board (Hospital for Sick
Children), prior to implementation. Patients, parents and legal guardians were informed
of the purpose of the study, expected length of participation and the anticipated
involvement of the patient in the study. Patients, parents and legal guardians were
informed of their right to refuse participation and to withdraw their child from the study
at any time. In the event of refusing participation, patients, parents and legal guardians
were reassured that their health care services would not be affected in any way. Verbal
and written consent for participation in the prospective trial was obtained prior to
enrolment. Patient rights (including confidentiality) were protected for all information
entered into the database. Data were stored in secured locations and electronic data was
password protected. All analyses arising from this study are available to the patients,
parents or legal guardians at their request.
59
3.7 FUTURE BENEFIT
The ability to predict those children with erolm's disease who will do poorly
could have significant clinical applications. Health care providers, patients and their
families could use this information to provide an overview of the anticipated clinical
course. Additionally, it may help select the most appropriate candid~tes for enrolment in
future studies assessing the early use of immunosuppressive therapies. •
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Chapter 4 - RESULTS
4.1 DESCRIPTIVE STATISTICS
One hundred sixty-one Crohn's disease patients less than 17 years of age at
diagnosis were assessed at the Hospital for Sick Children, Toronto between July 1997
and May 2001. Of these patients, 21 did not meet the inclusion/exctusion criteria of this
study. Twenty were removed due to inadequate baseline data as the initial diagnosis was
made outside the Hospital for Sick Children and one patient refused to participate. Eight
others were lost to follow-up prior to 8 months after diagnosis, precluding assignment of
the outcome variable. As such, 132 patients were entered into this study, of which 122
patients (92.4%) had complete baseline and follow-up data available for analysis.
(Separate analyses were done on the set of 122 patients with complete data and the set of
132 of which 10 cases were missing some baseline data).
Of the 122 patients with complete data, 44 (36.1%) were female and the average
age at diagnosis was 13.10 +/- 2.37 years. At the end of the first year following
diagnosis, 35 (28.7%) had quiescent disease, 38 (31.2%) mild disease, 29 (23.8%)
moderate disease (intermittent exacerbations) and 20 (16.4%) severe disease (clu'onically
active) (Figure 4.1).
Thirty patients (24.6%) had disease involving the large bowel only, 62 patients
(50.8%) had disease of both the small and large bowel, 28 patients (23.0%) had disease of
the small bowel only and 2 patients (1.6%) had isolated perianal disease.
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Severe
(16.3%)
Quiescent
(28.7%)
Mild
(31.20/0)
Figure 4.1
(0=122)
Percentage of Patients with Quiescent, Mild, Moderate and Severe Disease
During the First year Following Diagnosis.
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For initial treatment. 61 patients (50.0%) received systerjdic corticosteroids, 57
(46.7%) antibiotic treatment (ciprofloxacin and/or metronidazole), 43 (35.2%) 5-
ASA/sulphasalazine,5 (4.1%) budesonide, 7 (5.7%) azathioprine and 11 (9.0%) enteral
nutrition. Over the first year, 69 (56.6%) received at least one course of steroids and 37
(30.3%) were started on immunosuppressant therapy (34 azathiophne, 2 methotrexate
and 1 both). Fourteen patients (11.5%) underwent surgical intervention (4 ileocecal
resection, 2 subtotal colectomy, 2 drainage of intra-abdominal abscess, 3 diversional
ileostomies, 2 incision and drainage of perianal abscess, 1 perianal fistulectomy).
As previously stated, in the initial analysis, patients with quiescent and mild
disease were grouped together as were those with moderate and severe disease. Overall,
49 patients (40.2%) had moderate/severe disease over the first year of follow-up. This
was comparable to that observed in our post-hoc analysis where 43.4 percent of patients
had moderate/severe disease over the first year of follow-up.
4.2 DEMOGRAPHICS OF PATIENTS WITH INCOMPLETE DATA
Eighteen enrolled patients had insufficient data to enable analyses. Eight subjects
had insufficient follow-up to assess the primary outcome of disease severity and ten
subjects had incomplete baseline data. As demonstrated in Tables 4.1 and 4.2, these
patients had similar baseline demographics to those analyzed.
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Table 4.1 _ Baseline Demographics of Patients with Inc2.mEI~teData: Categoric~..1"yariables
Variable Lost Follow-up Complete Sets p Value (2-sided)
(0=18) (0=12.2.) F!sher
Female Gender
Initial Hospitalization
Initial Steroids
Initial Response
(Complete vs
PartiallNo Response)
Disease Location
Small Bowel Only
Small/Large Bowel
Large Bowel Only
10
11 (n=15)
44
43
61
86
28
62
30
64
1.000
0.297
0.802
1.000
0.079
0.451
0.247
...:!'able 4.2 Baseline D~.?graphics o!Patients with Incomplete Data: Continuous Var~a~_le_s _
Variable Lost Follow-up Complete Sets p Value (2-sided) P Value
(J?:=18) (n~l.~~)__ _ _~!~_dent t ~ann-'Y.I!!!_J?:~XU
Age at Diagnosis (years) 12.52 (2.55) 13.10 (2.37) 0.337
Baseline ESR (mm/hr) 37.00 (18.72) 48.25 (24.51) 0.125
Baseline PCDAI 37.83 (13.29) 37.70 (14.71) 0.974
Baseline Albumin (giL) 32.79 (4.71) 32.39 (5.01) 0.778
Baseline Platelets (109/L) 423.60 (157.20) 445.90 (127.70) 0.547
Mean (SD)
0.332
0.118
0.899
0.986
0.723
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4.3 UNIVARIATE ANALYSIS
Fisher's exact test for categorical variables showed no significant association
between disease severity and gender (p=O.701) or disease location, small bowel only
(p=O.827), small and large bowel (p=0.465) and lar~ bowel only (p~O.207) (Table 4.3).
Initial steroid usage (p=O.003) (Figure 4.2), initial hospitalization (p:!:O.004) (F'igure 4.3)
and partial/no response following initial induction therapy (p=O.028) (Figure 4.4) were
associated with moderate/severe disease over the first year after diagnosis.
Student's t-test was performed on continuous variables, assuming a normal
distribution Crable 4.4). Hypoalbuminemia (p=O.043) (Figure 4.5) and elevated baseline
PCDAI scores (p<O.OOOI) (Figure 4.6) were significantly associated with
moderate/severe disease over the course of the first year following diagnosis. Age at
diagnosis (p=O.292) and initial ESR (p=O.073) were not associated with disease severity.
Analysis of the data using the four-category outcome variable obtained similar
results, as did analysis using all patients (n=132) (Appendix E).
Secondary analysis failed to identify an association with disease severity and
positive family history of IBD (p=O.0687), baseline platelet count (p=O.324) or duration
of symptoms prior to diagnosis (p=O.582).
In addition, baseline PCDAI scores were not associated with disease location
(p=O.624) nor with duration of symptoms prior to diagnosis (p=0.470).
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Table 4.3 _ UIivariate Analysi!: ~ategorical Variables
Variable QuiescentlMiId Moderate/Severe p Value Relative 95% Confidence
Disease Disease (Fisher Risk Interval
n~~~ 2-sided)
Female Gender 25
...
19 0.701 1.123 0.723 - 1.743
Initial Hospitalization 18 25 0.004 1.914 1.258 - 2.910
Initial Steroids 28 33 0.003 2.063 1.276 - 3.334
Initial Response 16 20 0.028 1.648 1.087 - 2.498
(Partial/No Response vs
Complete Response)
Disease Location
Small Bowel Only 16 12 0.827 1.089 0.663 - 1.788
Small/Large Bowel 35 27 0.465 1.188 0.767 - 1.838
Large Bowel Only 21 9 0.207 0.690 0.381 - 1.250
-
Positive Family History of IBD 20 (n=68) 16 (n=48) 0.687 1.080 _ ... 0':76"9 - 1.521
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Table 4.4 Univariate Analysis: Continuous Variables
------- Quiescent/Mild Moderate/SevereVariable p Value
Disease Disease
(n~ ____~2)
Age at Diagnosis (years) 12.92 (2.50) 13.38 (2.15) 0.292
Baseline ESR (mm/hr) 45.00 (21.03) 53.10 (28.47) 0.073
Baseline Albumin (g/L) 33.44 (4.88) 30.83 (4.83) 0.004
Baseline PCDAI 33.53 (12.69) 43.93 (15.43) <0.001
Baseline Platelets (109/L) 436.51 (133.19) 459.84 (118.90) 0.324
Duration of Symptoms (months) 9.58 (11.35) 8.43 (11.12) 0.582
Mean (SD)
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Albumin
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Moderate/Severe
(n=49)
Figure 4.5 Plot of baseline albumin for quiescent/mild and moderate/severe disease. Bars indicate 95% confidence
interval for mean albumin levels.
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Figure 4.6 Plot of baseline PCDAI scores for quiescent/mild and moderate/severe disease. Bars indicate
95% confidence interval for mean of baseline PCDAI scores.
73
4.4 MULTIVARIATE LOGISTIC REGRESSION MODELS
Mulitvariate logistic regression models using backward stepwise selection were
constructed. All variables that were significant in the univariate analysis at a level of
p</=0.05 were entered. Gender was added to the motlel, despite not Jreing significant in
the univariate analysis, as it is an important demographic factor. N,o interaction terms
were significant. As illustrated in Table 4.5, baseline PCDAI scores' is the best single
variable predictive of future disease severity over the first year following diagnosis,
accounting for 16.3% of the variability of the model. It is also the only variable that
remained statistically significant in the multivariate analysis. This compares to the full
model (including all five variables and gender) which accounts for 23.0% of the
variability. Model 4, which contains three variables (baseline PCDAI, initial
corticosteroid use and response to initial therapy), was the best simplified model
accounting for 21.6% of the variability. However, this model contained two covariates
(initial corticosteroid use and response to initial therapy) which were not found to be
significant in the multivariate regression analysis.
The presence of multicollinearity between the variables was evaluated for each
model. As demonstrated in Table 4.6 the correlation coefficients for the explanatory
variables in each model ranged from -0.382 to +0.482.
ROC curves were constructed for each of the models listed in Table 4.5 and are
plotted in Figure 4.7 for models 1,4 and 6. The area under the curve ranged from 0.744
to 0.688 as noted in Table 4.7.
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Table 4.5 Multivariate Analysis: Logistic Regression Models
Model Covariate Regression Standard p Odds 95% CI Percent Nagelkerke
.~_~~ffic!e'!t....._ ~r~!:lt:. Value .__!!..a!!!> ________ . __._~~.!l~~r<!~~!- _ R2
Intercept -1.340 2.173 0.537 0.262 70.5 0.230
PCDAI 0.029 0.021 0.157 1.030 0.989 - 1.072
Albumin -0.028 0.051 0.579 0.972 0.880 - 1.074
Initial Hospital (Yes) 0.510 0.459 0.267 1.665 0.677 - 4.092
Initial Steroids (Yes) 0.714 0.449 0.112 2.041 0.847 - 4.922
Initial Response (Partial/No Response) 0.641 0.455 0.159 1.898 0.778 - 4.629
Gender (Male) -0.076 0.426 0.858 1.079 0.468 - 2.487
Intercept -1.426 2.117 0.500 0.240 69.7 0.230
PCDAI 0.029 0.021 0.154 1.030 0.989 - 1.072
Albumin -0.027 0.050 0.588 0.973 0.881 - 1.074
Initial Hospital (Yes) 0.515 0.458 0.260 1.674 0.683 - 4.104
Initial Steroids (Yes) 0.713 0.449 0.112 2.040 0.846 - 4.915
Initial Response (Partial/No Response) 0.651 0.452 0.150 1.917 0.791 - 4.644
Intercept -2.520 0.666 <0.001 0.080 68.9 0.227
PCDAl 0.035 0.018 0.056 1.035 0.999 - 1.073
Initial Hospital (Yes) 0.494 0.455 0.278 1.639 0.671 - 4.002
Initial Steroids (Yes) 0.733 0.446 0.101 2.081 0.867 - 4.991
Initial Response (Partial/No Response) 0.672 0.450 0.135 1.958 0.811 - 4.121
Intercept -2.623 0.662 <0.001 0.073 71.3 0.216
PCDAI 0.041 0.017 0.016 1.042 1.008 - 1.078
Initial Steroids (Yes) 0.742 0.443 0.094 2.100 0.881 - 5.004
Initial Response (Partial/No Response) 0.780 0.436 0.074 2.182 0.928 - 5.127
75
Table 4.5 Multivariate Analysis: Logistic Regression Models continued
Model Covariate Regression Standard p Odds 95% CI Percent Nagelkerke
Coefficient Error Value R~~!~ Concordant R2
Intercept -2.649 0.654 <0.001 0.071 68.9 0.189
PCDAI 0.053 0.016 0.001 1.054 1.022 - 1.087
Initial Response (Partial/No Response) 0.712 0.413 0.098 2.038 0.876 - 4.738
Intercept -2.531 0.636 <0.001 0.080 67.2 0.163
PCDAI 0.055 0.016 <0.001 1.057 1.025 - 1.090
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Figure 4.7 Receiver Operating Characteristic Curves of Multivariate Models 1,4 and 6.
Modell: baseline PCDAI, initial steroids, initial response, initial hospitalization,
baseline albumin, gender;
Model 4: baseline PCDAI, initial steroids, initial response;
Model 6: baseline PCDAI
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Table 4.6 Correlation Coefficients
PCDAI Response Initial Steroids Initial Hosp Albumin Gender
PCDAI .024 -.288 -.320 .482 .057
Response .024 .124 -.201 .093 .118
Initial Steroids -.288 .124 . -.008 .070 -.014
Initial Hosp -.320 -.201 -.008 -.087 .066
Albumin -.482 .093 .070 -.087 .091
Gender .057 .118 -.014 .066 .091
PCDAI .017 -.287 -.324 .479
Response .017 .127 -.211 .083
Initial Steroids -.287 .127 -.007 .072
Initial Hosp -.324 -.211 -.007 -.094
Albumin .479 .083 .072 -.094
PCDAI -.026 -.365 -.317
Response -.026 .117 -.209
Initial Steroids -.365 .117 -.003 ,
Initial Hosp -.317 -.209 -.003
PCDAI -.089 -.382
Response -.089 .121
Initial Steroids -.382 .121
.. ....
-
-
PCDAI -.054
Response -.054
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Table 4.7 Area Under the Curve of Multivariate Models
Standard Asymptotic
~Q! __§ ig!!ifica.!!..ce1
Model
1
2
3
4
5
6
AVC
0.744
0.738
0.736
0.733
0.711
0.688
0.046
0.046
0.046
0.047
0.048
0.049
<0.001
<0.001
<0.001 ..
<0.001
<0.001
<0.001
Asymptotic 95% CI
0.654 - 0.834
0.648 - 0.829
0.645 - 0.827
j).641 - 0.825
0.617 - 0.806
'Oj592 - 0.783
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Hosmer and Lemeshow's goodness-of-fit test statistic for all the models ranged
between 0.303 and 0.900, and was in support of well-fitting models. Examination of
standard residuals failed to identify any outliers.
The estimated odds ratio (moderate/severe disease) for the m9del containing only
PCDAl as a predictive factor was 1.057 (95% Cl, 1.025-1.090) per 2.5 units PCDAL
The odds ratio (moderate/severe disease) for each change in PCDAl ranged from 2.41 to
18.17 (Figure 4.8). The odds ratio for moderate/severe disease was highest for PCDAl
scores> 15, >62.5 and >65 at 11.17, 18.17 and 14.54 respectively.
Subsequent analysis of the data stratifying the outcome variable into four groups
showed similar results, with baseline PCDAl being the best single independent
prognostic factor of disease severity (Appendix F).
4.5 CDEIS SCORES
CDElS scores were prospectively collected and recorded independently on 13
patients. Nine patients had quiescent/mild disease and four had moderate/severe disease.
The intraclass correlation as a measure of inter-rater reliability was 0.948 (95% Cl,
0.840-0.984) and 0.891 (95% CI, 0.636-0.967) for CDElS and visual analog scores
(VAS) respectively. Pearson correlation for the VAS and CDElS scores were 0.792
(p<0.01) and 0.801 (P<O.Ol) for those ranked by JC and the other raters, respectively.
The CDElS score was not associated with disease severity over the first year following
diagnosis (p=0.877) nor was the VAS (p=0.534).
80
20.0
Q) 17.5
s...
Q)
o > 15.0
.- Q)..-...
"""CJ)Q)~ ........ tn 12.5
LL.Q)ctS
~ ~.~ 10.0
-0 Q)C 750-0 .
o
:!: 5.0j. -. • ••
. . . ..
2.5 • • • • • • •
0.0 I I I I I I I I I I I I I I I I I
o 5 10 15 20 25 30 35 4045 50 55 60 65 70 75 80 ~
Baseline peDAl Score
Figure 4.8 Odds Ratio for Each Change ofPCDAI Score
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Of note, administration of the CDEIS was conducted on1y from August 2000
through May 2001. During this period, the CDEIS was completed in 13 (of 16 eligible)
patients, representing an 81.3% collection rate. Of the 3 patients who did not complete a
CDEIS evaluation, 1 patient had initial colonoscopy performed at an 9utside hospital and
4
2 patients did not undergo colonoscopy prior to treatment.
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4.6 VALIDATION OF PRIMARY OUTCOME VARIABLE
As previously discussed, no validated instrument of disease severity in Crohn's
disease was available prior to commencement of this study. The primary outcome
variable chosen was similar to those used in other -studies on pediatric Crolm's disease
(48;80;91). This study was designed to concomitantly validate the outcome variable by
evaluating how well it compared with other surrogate markers of di ease severity that
were not included in the outcome variable definition. Total days hospitalized, number of
hospitalizations, IMPACT scores, linear growth and mean PCDAI scores were pre-
selected as likely markers of disease severity.
Correlation of the a priori constructs are reported in Table 4.7.
The average duration of hospitalization was longer for patients with
moderate/severe disease compared to quiescent/mild disease (14.8+/-16.5 vs 5.1+/-12.5
days, p=O.OOI). If the hospitalization at diagnosis was removed from the analysis, the
average duration of hospitalization for patients with moderate/severe disease remained
longer compared to quiescent/mild disease (7.9+/-12.1 vs 1.5+/-6.09 days, p<O.OOl).
Furthermore, patients with moderate/severe disease averaged more hospitalizations
compared to patients with quiescent/mild disease (1.2+/-1.3 vs 0.5+/-0.8, p<O.OOl).
Total days hospitalized (p<O.OOI), days hospitalized after diagnosis (p<0.001) and
total number of hospitalizations (p<O.OOI) were all significantly associated with more
severe disease when analyzing with the four-category outcome variable (Appendix G).
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Table 4.7 Construct Validity Testing
Construct
Disease severity should reflect total length of
hospitalization
Disease severity should reflect length of
hospitalization, excluding hospitalization at diagnosis
Disease severity should reflect number of
hospitalizations
Disease severity should reflect quality of life, as
measured by IMPACT scores at one year after
diagnosis
Disease severity should reflect quality of life, as
measured by IMPACT scores at six months after
diagnosis
Disease severity should reflect disease activity over
time, as measured by mean PCDAI scores at 6 and 12
months
Disease severity should reflect linear growth, as
measured by change in z-scores from end of first year
and diagnosis
Analysis r p
Correlation between disease severity and total length of 0.35 <0.0001
hospitalization
Correlation between disease severity and total length of 0.41 <0.0001
hospitalization, excluding hospitalization at diagnosis
Correlation between disease severity and number of 0.34 0.0001
hospitalizations
Correlation between disease severity and quality of life, -0.39 0.043
as measured by IMPACT scores at one year after
diagnosis
Correlation between disease severity and quality of life, -0.73 0.001
as measured by IMPACT scores at six months after
diagnosis
Correlation between disease severity and disease 0.36 0.0005
activity over time, as measured by mean PCDAI scores
at 6 and 12 months
Correlation between disease severity and linear growth, -0.18 0.044
as measured by change in z-scores from end of first
year and diagnosis
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IMPACT scores were completed at six months after diagd'~sis in 18 patients, of
which 10 patients had moderate/severe disease and 8 had quiescent/mild disease. The
average IMPACT score for moderate/severe disease was significantly lower compared
with quiescent/mild disease (152.9+/-25.6 vs 197.2+7:=19.0, p=O.OOI).
Similarly, IMPACT questioill1aires were completed at one yea; after diagnosis in
27 patients, of which 14 patients had moderate/severe disease and 13 quiescent/mild
disease. The average IMPACT score [or patients with moderate/severe disease tended to
be lower compared to quiescent/mild disease (154.9+/-40.1 vs 179.5+/-29.9, p=0.084).
There were a number of reasons why only a proportion of the patients had
IMPACT scores calculated. First, due to its design, the IMPACT questiOlmaire was not
administered to children <10 years of age. Second, administration of the IMPACT
questionnaire was conducted only from August 2000 through to May 2002. As such, 18
patients completed the 6-month questionnaire of 21 eligible patients (85.7%); and 27
patients completed the 12-month questionnaire of 43 eligible patients (62.8%).
Analysis of IMPACT scores was not performed with the four-category outcome
variable due to insufficient numbers in some groups.
PCDAI scores were collected at the 6 \\leeks, 6 months and 12 months visits. For
purposes of this analysis, the association of the average PCDAI scores collected from the
6 and 12-month visits to disease severity was assessed. The average PCDAI score was
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higher for the group with moderate/severe disease (15.9+/-11.7, if=36) compared to the
group with quiescent/mild disease (8.0+/-7.3, n=53) (p=O.OOl) (Figure 4.9). (Not all
patients had bloodwork collected at both the 6 and 12 month visits, thus precluding
calculation of the mean PCDAl score in those patients).
Similarly, higher mean PCDAl scores were associated with more severe disease
(p<O.OO 1) when analyzing using the four-category outcome variable (Appendix G).
Height was measured at all visits and converted to z-scores. The height z-scores
were low at baseline and one-year follow-up in both the moderate/severe and
quiescent/mild groups. The baseline height z-scores for moderate/severe disease was
comparable to quiescent/mild disease (-0.708+/-1.038 vs -0.632+/-1.259, p=0.726) (r=-
0.060, p=0.51); as were those at one-year follow-up, moderate/severe disease and
quiescent/mild (-0.762+/-1.083 vs -0.486+/-1.112, p=0.1763) (r=-0.14, p=0.13). Of
note, the change in z-scores between one-year follow-up and baseline were significantly
lower for patients with moderate/severe disease compared to those with quiescent/mild
disease (-0.054+/-0.381 vs 0.146+/-0.571, p=0.045) (r=-0.18, p=0.044). Similar results
were obtained when analyzing height with the four-category outcome variable, though
the association between disease severity and change in z-scores did not quite reach
significance (p=0.065) (r=-0.16, p=0.082) (Appendix G).
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Figure 4.9 Plot of mean peDAl scores (measured at 6 and 12 months) for quiescent/mild and moderate/severe
disease. Bars indicate 95% confidence interval for mean scores.
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Reliability
Kappa statistic for intra-rater agreement was 0.898 and 0.856 for the two-category
and four-category disease severity outcome variable respectively. Similarly, kappa
statistic for inter-rater agreement was 0.900 and 0.-846 for the two-category and four-
category disease severity outcome variable respectively.
For the four-category variable, thirteen (10.7%) responses were disconcordant
with intra-rater assessment and nineteen (15.6%) were disconcordant with inter-rater
assessment. Of the disconcordant response for intra-rater assessment, twelve (92.3%)
were separate by only one category and one (7.2%) was separated by two categories.
Similarly, of the disconcordant responses for inter-rater assessment, seventeen (89.5%)
differed by only one category and two (10.5%) differed by two categories. When
reduced to a two-category outcome variable, six (4.9%) responses remained
disconcordant for both the intra-rater and inter-rater assessments.
Feasibility
Both raters (JC, AG) reported that the outcome variable definition was easy to use
and they were each able to provide an outcome variable assignment for all the cases.
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4.7 CASE-CONTROL STUDY: EARLY IMMUNMODULAtOR USE
As previously discussed, several studies (75;76) presented data demonstrating that
early use of immunosuppressive therapy in pediatric-onset Crolm's disease leads to
improved outcomes. To further assess this, the thesis cohort was utilized to conduct a
case-control analysis on those patients who were started on immunstppressant therapy
I
within the first 30 days of diagnosis, randomly matching each case with seven controls.
As the baseline PCDAI was identified to be the primary prognostic factor for disease
severity over the course of the first year, cases and controls were matched for baseline
PCDAL
lmmunomodulator therapy was started on seven patients (6 azathioprine, 1
methotrexate) within the first 30 days of diagnosis. As demonstrated in Table 4.9, cases
and controls were similar for baseline PCDAI, baseline ESR, baseline albumin, age at
diagnosis, gender, and disease location (ileum, colon).
Five patients (71.4%) of those receiving immunomodulator therapy within 30
days of diagnosis had a quiescent/mild disease course over the following year as
compared to 25 (51.0%) controls (p=0.431).
Similarly, immunomodulator therapy was initiated on 11 patients (10
azathioprine, 1 methotrexate) within 90 days of diagnosis. A case-control analysis
matching for baseline PCDAI was conducted, randomly matching each case to 3 controls.
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Table 4.9 Early Immunomodulation Therapy «30days): Baseline Characteristics
Variable Immunomodulator
(n=7)
No Immunomodulator
(n=49)
p Value
(Student's T)
p Value
(Mann Whitney U)
Baseline PCDAI
Baseline ESR (mm/hr)
Baseline Albumin (giL)
Age at Diagnosis (years)
Female Gender
Ileal Involvement
Colon Involvement
M"'~"(5i.D)
47.86 (12.11) 46.53 (12.98) 0.800
65.71 (20.62) 56.12 (24.88) 0.336
29.86 (4.45) 30.56 (4.19) 0.681
12.46 (2.25) 13.64 (2.24) 0.197
18 1.00 (Fisher)
33 0.679 (Fisher)
29 0.237 (Fisher)
90
0.610
0.282
0.716
0.185
As demonstrated in Table 4.1 0, cases and controls were similar!ofor baseline peDAl,
ESR, albumin, age at diagnosis, gender and disease location (ileum, colon).
Six patients (54.5%) of those receiving immunomodulator therClPY within 90 days
~
of diagnosis had a quiescent/mild disease course over the following ye/ar as compared to
13 (39.4%) of controls (p=0.489).
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Table 4.10 Early Immunomodulation Therapy «90days): Baseline Characterisitcs
Variable Immunomodulator No Immunomodulator p Value
(n=l1) (n=33) (Student's T)
Baseline PCDAI 49.55 (10.89) 49.24 (13.98) 0.948
Baseline ESR (mm/hr) 63.91 (19.57) 53.58 (26.09) 0.236
Baseline Albumin (giL) 28.82 (4.45) 29.91 (4.84) 0.499
Age at Diagnosis (years) 13.15 (2.32) 13.36 (1.95) 0.787
Female Gender 5 10 0.468 (Fisher)
Ileal Involvement 6 20 0.738 (Fisher)
Colon Involvement 10 22 0.240 (Fisher)
Mean (SD)
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p Value
(Mann Whitney U)
0.708
0.130
0.574
1.000
Chapter 5 - DISCUSSION
5.1 DISCUSSION
This thesis clearly illustrates the wide inter-patient heterogeneity in the clinical
course of Crolm's disease, with 59.8 percent of patients having quiel'cent/mild disease
~
and 40.2 percent having moderate/severe disease. This spectrum of,disease severity is
similar to that observed in the post-hoc analysis (51.8% qUiesce~t/mild) and the
Munkholm study (55% mild) (44).
Additionally, the data demonstrates the considerable intra-patient variability in the
clinical course of Crohn's disease, as many patients alternate between quiescent/mild
disease and moderate/severe disease. However, importantly the post-hoc analysis clearly
indicates a relationship between disease severity from year to year, as patients with
quiescent/mild disease in anyone year are more likely to continue to have quiescent/mild
disease in the following year. Likewise, those patients with moderate/severe disease in
any given year are at higher risk of having moderate/severe disease in subsequent years.
These results are similar to those published by Munkholm et al (44).
The datu supports the hypothesis that disease activity at diagnosis is predictive of
disease severity. Patients with high disease activity at the time of diagnosis were clearly
shown to be at increased risk for a moderate/severe course over the subsequent year.
Several variables used to estimate disease activity were predictive of subsequent disease
severity, including PCDAl, albumin level, initial corticosteroid use, initial hospitalization
and initial response to therapy. Multivariate analysis indicated that baseline PCDAl
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score was the best single factor predictive of disease severity. Tli~ highest odds ratios
were found at both ends of the PCDAl scale (> 15, >62.5 and >65), demonstrating that
very low scores (<1=15) were most predictive of quiescent/mild disease over the first year
and very high scores (>62.5) were most predictive of moderate/severe <fisease.
~
While this study identifies several clinical parameters whi~h have value in
predicting disease severity, only a small proportion of the variability (Nagelkerke
R2=0.230) was explained by the full six-variable logistic regression model. For this
reason, one cannot reliably use this model to predict outcome for individual cases.
However, the data provides evidence to support targeting patients with higher disease
activity for early immunosuppressant therapy, as these patients are at increased risk to
experience a more severe clinical course. This is supportive of the study by Markowitz et
al (75) who selected patients with moderate-severe disease activity at baseline for early
introduction of i,nununosuppressive therapy.
The model that includes baseline PCDAl, initial corticosteroid therapy and
response to initial therapy is superior in its predictive ability to the model using only
baseline PCDAl (Nagelkerke R2 0.216 8nd 0.163 respectively). However, as many
subjective factors, including patient, parent and physician biases can influence the choice
of initial therapy and thus response, the model using PCDAl alone is arguably the best
objective model to employ, albeit with some loss of predictive power. Additionally, this
was the only model that did not contain non-significant covariates in the multiple
regression analyses. Furthermore, it is important to emphasize that the prognostic ability
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j.1
of all the models should be verified against other similar prospectively assembled
cohorts.
The importance of an appropriate and vaii'd outcome var~ble in conducting
~
clinical trials cannot be over emphasized. For this reason, great a~tention was paid to
defining the primary outcome variable of disease severity. These criteria were
objectively defined, based upon symptom pattern and the potency of medication,
specifically the need for corticosteroids, enteral nutrition or surgery.
Versions of the outcome variable had been used in other studies studies
(48;80;91) but had not been systematically evaluated. Therefore, validation of the
primary outcome variable for feasibility, construct validity and reliability was conducted
within the study design. Both scorers rated the outcome variable classification as easy to
use. Construct validity was demonstrated by proving significant association of
moderate/severe disease with longer hospitalization, greater number of hospitalizations,
impairment of linear growth, higher mean PCDAI scores and lower IMPACT scores at 6
months. There was also a trend towards lower IMPACT scores at 12 months. Of note,
Otley et al (91) also demonstrated a relationship between more severe disease (similar
definition of disease severity) and lower IMPACT scores. Griffiths et al (48) reported a
similar significant association between more severe disease (similar definition of disease
severity) and impaired linear growth.
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Furthermore, both intra-rater and inter-rater reliability were ~·trong as evaluated by
high kappa statistic for each (0.898 and 0.856 respectively for the two-category variable;
0.900 and 0.846 respectively for the four-category variable). Not surprisingly, with the
four-category variable, most of the disconcordant responses for both intra-rater and inter-
rater assessments were separated by only one category (92.3% and 89.5%, respectively).
This indicates that most of the disagreement occurred among consecutive categories.
As is evident, the correlation coefficients in the construct validity assessment
tended to be in the mild to moderate range (0.3 <lrl<0.5). That is to be expected since our
outcome variable of disease severity is multidimensional and should not be expected to
have high correlation with anyone of the independent variables used to validate it. That it
did behave in the predicted marmer, albeit with mild to moderate correlation, to the a
priori constructs (each measuring a different entity), is evidence in support of the
measure's multi-dimensional validity.
Contraction of the outcome variable into two-categories from four-categories was
justified on the basis that the moderate and severe disease groups were more similar then
dissimilar, as were the quiescent and mild disease groups. The moderate and severe
disease groups both experienced significant symptoms and received the more aggressive
therapies compared to the quiescent and mild disease groups. As such, it was judged to
be more relevant clinically to combine the moderate and severe disease groups into one,
as the risk/benefit ratio for the early introduction of immunosuppressive therapies may be
more favorable for this group. As the reliability of a scale decreases as fewer categories
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are used (93), analyses were performed with both the two-category and four-category
variable to check for any adverse effect with using the contracted form as the primary
outcome measure. As was shown, similar results were observed. The finding of similar
results between the two-category and four-category olltcome variable further supports the
choice of using the two-category outcome variable as it is a simp1ified version that
t
provides similar clinically significant discrimination.
The case-control analysis did not demonstrate a significant reduction in disease
severity in the group receiving early immunosuppressive therapy. However the number
of patients receiving immunomodulator therapy within 30 (n=7) and 90 (n=11) days of
diagnosis was small. Thus this analysis was under-powered to detect a statistical
difference. However, the study does reveal a trend towards a higher proportion of
patients experiencing quiescent/mild disease in the early immunosuppressant groups
compared to the matched controls (71.4% vs 51.0%, </=30days; 54.5% vs 39.4%, </=90
days). This trend was in support of the findings from the randomized controlled trial of
Markowitz et al (75), where patients with moderate-severe disease activity at diagnosis
who received 6-mercaptopurine had better outcomes then those who did not.
5.2 STUDY STRENGTHS
The maintenance of a prospectively compiled database was essential for both the
post-hoc analysis and the thesis cohort study to be completed. Due to referral patterns the
post-hoc analysis very closely approximated population-based data for childhood Crohn's
disease. As such, the influence of referral bias was low and the data from this study
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should accurately reflect the clinical course of childhood Crohn's ~isease. Furthermore,
the high rate of follow-up in the thesis cohort study was important in ensuring the
generalisability of the analyses.
As no gold standard exists for the diagnosis of Crohn's diseas~, misclassification
and reclassification can be problematic. As noted, 10-15 percent of colitis cases are
initially classified as 'indeterminate', and up to 3 percent of patients with Crohn's disease
or ulcerative colitis are reclassified during follow-up (19;42). While this is a potential
problem with all studies in inflammatory bowel disease, the application in this study of
accepted definitions of Crohn's disease, ulcerative colitis and indeterminate colitis should
have minimized the possibility of misclassification.
The validation of the primary outcome variable was very important in ensuring
the accuracy and generalisability of this study.
Eighteen patients were not included in the initial analysis secondary to having
incomplete data (eight were lost to follow-up and ten had incomplete baseline data
collected). There were no appreciable differences in the baseline demographic data of the
18 patients with incomplete data and the 122 analyzed. As such, exclusion of these
patients from the analysis should not be expected to appreciably affect the conclusions.
As a further test, all analyses were conducted on the cohort of 132 patients (comprised of
the 122 patients and the 10 with incomplete baseline data). The results were similar.
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5.3 STUDY LIMITATIONS j.'
Disease location was not found to be associated with future disease severity in our
study. Munkholm et al (44) also found no association between disease location and
disease course. However, it is important to note that our analysis was performed on
relatively small numbers (particularly perianal disease - 2 patients)~ and thus a larger
sample size may have detected a difference. Similarly, the small nurrtber of completed
CDEIS (n=13) and IMPACT (n=18 and n= 27 at 6 and 12 months respectively) scores
could have resulted in type II error in the analysis. Therefore, caution must be used in the
interpretation of these results.
As this study was conducted in a tertiary care referral hospital it is likely that a
higher percentage of patients with more severe disease were represented in the thesis
cohort than would be expected in the J10lmal population. While this referral bias would
represent a significant methodological error for a natural history study, it should have
minimal impact on the cohort study designed to identify prognostic factors, since the
inflammatory bowel disease clinic at the Hospital for Sick Children also provides primary
care to Crohn's disease patients in the region. Thus, the entire spectrum of disease
severity in pediatric Crohn's disease would have been represented in the study group.
5.4 DIRECTIONS FOR FUTURE RESEARCH
This study examined factors predictive of disease severity only over the first year
following diagnosis. Future studies should assess the presence of prognostic factors for a
longer period of time.
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As stated, the multivariate regression models explained only a small proportion of
the variability in disease severity. Identification of other prognostic variables would
increase the prognostic ability of these models.. As our und~rstanding of the
pathophysiology of Crolm's disease evolves, future studies should exa1nine the predictive
value of other entities including TNF-alpha levels, baseline titers for ASCAIANCA and
mutations of associated genes, such as NOD2/CARD15. Furthermore, such studies
should also evaluate clinical variables that were not evaluated in this study (including
exposure to breast-feeding, smoking history and presence of anemia). As Crohn's
disease is heterogeneous, future work wi II need to focus on identifying parameters to
allow stratification of patients into individual treatment groups based upon their disease
characteristics and predicted behaviour. Additional work should be done to identify
prognostic factors in adult-onset Crohn's disease.
When conducting clinical trials it is imperative to have well defined and
appropriate outcome measures. The outcome measures should be standardized to
facilitate comparisons among different studies. To this end, validation of the primary
outcome variable was performed in this study. However, the disease severity
classification used in this study should be further validated against other independently
compiled cohorts.
Future work should also be done to improve the assessment of disease severity.
Disease severity is a multi-dimensional concept and such a measure should incorporate a
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variety of factors including symptoms, impact on daily life, ~otional and social
disturbances, potency of therapy and complications of therapy over time. This may best
be assessed through the development and validation of an index measure, as constructed
through the process of item generation, reduction and selection. Such rpeasures will need
4
to be rigorously validated in a manner similar to that performed in ,this study. Other
constructs should be incorporated in addition to the ones employed in this study,
including correlation with school/work days missed, and impact on each patient's
emotional well-being. Assessment by both patients/parents and physicians should be
included. Similarly, future work should address the need to develop other outcome
measures to be employed in clinical trials including assessments of severity of mucosal
inflammation and healing.
Future investigation must focus on the role of early immunomodulator therapy in
Crohn's disease. While Markowitz et al (75) provided preliminary evidence to support
the early use of immunomodulator therapy, other groups must confirm their observation.
This would most appropriately be performed within the setting of multi-center
randomized control trials targeting first those patients with high disease activity. Finally,
it is essential that well-defined outcome variables of disease severity be employed,
similar to those used in this study.
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Appendix A
1997 Toronto Census Metropolitan Area Jurisdictions
Ajax
Aurora
Bradford West Gwillimbury
Brampton
Caledon
East Gwillimbury
Georgina
Georgina Island First Nation
Halton Hills
King
Markham
Milton
Mississauga
Mono
New Tecumseth
Newmarket
Oakville
Orangeville
Pickering
Richmond Hill
Toronto
Uxbridge
Vaughan
Whitchurch-Stouffville
102
Appendix B
Criteria for Diagnosis of Crohn' s Disease (16)
Exclusion:
- Infections (microbiology, including Yersinia antibodies when appropriate)
- Ischemia (predisposing factors, distribution of disease, histolpgy)
- Irradiation (history)
- Lympl~oma/carcinoma (previous coeliac disease, suggestive,radiologic features,
prognosIs)
Inclusion:
a) Mouth to anus
- Chronic granulomatous lesion of the lip or buccal mucosal (inspection, biopsy)
- Pyloro-duodenal disease (radiology, endoscopy, biopsy)
- Small-bowel disease (radiology, endoscopy, specimen)
- Chronic anal lesion (clinical, examination, biopsy)
b) Discontinuous
- Lesions separated by normal mucosa, which may be widely separate, or 'skip
lesions' along the length or around the circumference, or discrete ulcers
(endoscopy, radiology, specimen)
c) Transmural
- Fissuring ulcers (radiology, specimen)
- Abscess (clinical imaging)
- Fistula (clinical, imaging)
d) Fibrosis
- Stricture (to be distinguished from carcinoma or concentric muscular thickening
in DC), which can be asymmetric and multiple (endoscopy, radiology, specimen)
e) Lymphoid
- Biopsy of small apthoid ulcer or showing lymphoid aggregates
f) Mucin
- Retention of colonic mucin on biopsy in the presence of active inflammation
(biopsy, specimen)
g) Granulomata
- Not present in all cases of Crohn's disease, distinguish from caseating
granulomata of tuberculosis, foreign-body granulomata, or other causes (biopsy,
specimen)
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Appendix C Pediatric Crohn's Disease Activity Index l
11-19 F: >/= 34 _(0) 15-19 M: >/= 37 _(0)
29-33 (2.5) 32-36 (2.5)
<29 =(5) <32 =(5)
HISTORY (Recall, 1 week)
Abdominal pain: None __ (0)
Mild - Brief, does not interfere with activities __ (5)
Mod/severe - daily, longer lasting, affects activities, nocturnal __(lO)
LABORATORY
HCT (%) <10 yrs: >33 _(0) 11-14 M: >/= 35 _(0)
28-32 _(2.5) 30-34 _(2.5)
<28 _(5) <30 _(5)
Patient functioning, General Well-Being (Recall, 1 week)
No limitation of activities, well __ (0)
Occasional difficulty in maintaining age appropriate activities,
Below par __ (5)
Frequent limitation of activity, very poor __(10)
__ (0)
(5)
==(10)
__ (0)
__ (5)
__(10)
(0)
--(5)
==(10)
(0)
==(5)
__(10)
_(0)
_(5)
_(10)
(Fever >/= 38.5 °C for 3 days over past week, definite arthritis,
Uveitis, e. nodosum, p. gangrenosum)
None
One
>/= Two
Follow-up:2
Height velocity >/= -I SO
Height velocity < -1 SO, > -2 SO
Height velocity </= -2 SO
Height
At Diagnosis:
< I channel decrease
>/=1, <2 channel decrease
>2 channel decrease
ill:
EXAMINAnON
Weight
Weight gain or voluntary weight stable/loss
Involuntary weight stable, weight loss 1-9%
Weight loss >/= 10%
Extra-intestinal Manifestations
Perirectal disease
None, asymptomatic tags
1-2 indolent fistula, scant drainage, no tenderness
Active fistula, drainage, tenderness, or abscess
Abdomen
No tenderness, no masses
Tenderness, or mass without tenderness
Tenderness, involuntary guarding, definite ~.ass
_____(0)
_(5)
____(10)
ESR (mm/hr) <20 __ (0)
20-50 __ (2.5)
>50 __ (5)
Albumin (g/dl) >/=3.5 __ (0)
3.1-3.4 __ (5)
</=3.0 __ (10)
Stools: (per day)
0-1 liquid stools, no blood
Up to 2 semi-formed with small blood, or 2-5 liquid
Gross bleeding, or >/= 6 liquid, or nocturnal diarrhea
TOTAL SCORE _
I Hyallls1Setal. Developlllent and validation of aped iatric Crohn'sdisease acti vityindex.
1PGN 1991;12:439-447.
1 Tanner 1M. Davies PSW. Clinical longitudinal standard height and height velocity for North
Alllericanchildren. lPed 1985; 107:317-329.
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Appendix D
IMPACT Questionaire
INSTRUCTIONS
On the next few pages you will find questions about many different issu . Some of
these questions are about physical symptoms; other deal with emotionj worries.
Underneath each question is a line. There is an answer A at one end oft e line and an
answer B at the other. Please put a mark anywhere on the line to show ~here your
feelings lie. You can put your mark at A, at B, or anywhere in between;wherever fits
best with your answer.
Here is an example:
How much do you like school?
A
I hate school.
B
I love s'hool.
You can put a mark on the line anywhere you want; wherever fits b t with how you
feel about school.
The instructions for all the questions that follow will be the same, but th points A and B
will have differ nt meanings depending on the question.
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Question 1: Put a mark anywhere on the line to tell how much yoar stomach has been
hurting recently. .
A
My stomach has been hurting so
much, the pain is as bad as it has
ever been, and comes all the
time; it's really hard to deal with.
B
1_ haven't had any stomach cramps at
all recently.
Question 2: Taking pills or medications is usually part of the treatment ofIBD. Put a
mark on the line to show how you feel about having to take medications.
A
I hate taking medications and I
get really upset and bothered
about having to take them.
B
I really don't mind at all when I
have to take medications.
Question 3: Some kids find that they get more stomach pain or diarrhea when they eat
certain foods. Put a mark on the line to show how eating affects you.
A
I can hardly eat anything at all;
whenever I eat, I get pain or I'm
running to the bathroom.
B
Nothing upsets my stomach; I can
eat anything I want.
Question 4: Your IBD may have been completely under control for a long time, or you
may have had flare-ups of symptoms. Do you worry about flare-ups? Put a mark on the
line to show how much you worry about having a flare-up.
A
Even if I'm feeling better I can't
enjoy it, because I can't trust it to
last. I'm always afraid of getting
sick again.
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B
I never worry about having a flare-
up.
Question 5: Your doctor and nurse have told you that medications ~~d other treatments
are used to keep your bowel condition under control, but not actually cure it. Put a mark
on the line to show how you feel about this.
A
IBD is going to be with me all
my life; it's horrible having
something that's lifelong. I can't
stop thinking about that.
B
I know that there is l't a cure for
IBD yet but I nevef worry about
that.
Question 6: Sometimes IBD (especially Crohn's disease) can affect your growth in
height. Put a mark on the line to show how you feel about your growth.
A
Being short is really awful for
me. If only I could be taller.
B
I am perfectly happy with my
height.
Question 7: Some kids and teenagers have trouble gaining weight because ofIBD, but
others find they gain too much weight. Put a mark on the line to show how much you
feel about your weight.
A
I'm miserable because of my
weight. If only I could change it.
B
I'm perfectly happy with my
weight.
Question 8: Some kids feel that IBD or the drugs sometimes used to treat it affect the
way they look. Put a mark on the line to show how you feel about the way you look.
A
I think I look awful.
107
B
I'm perfectly happy with the way I
look.
Question 9: Do you have enough energy to do the things you wanfto do?
A
I never have energy to do
anything; I'm so tired all the
time.
B
I have lots of energy; I can do as
much as my friends can do without
getting tired. '
Question 10: Do you feel you have to give up or miss out on things you would like to
do such as hobbies, just playing, going to parties or other special things?
A
I always have to stay out of
things; I feel like I'm missing out
on everything.
B
I can do all the things I like as much
as I want. I don't feel my bowel
condition gets in the way at all.
Question 11: How much does your bowel condition get in the way of going to school
normally?
A
I can't attend school normally at
all; I'm always having to stay
home.
B
I never have to miss school because
of my bowel condition.
Question 12: How much are you bothered by having diarrhea or gas?
A B
My life seems to be spent in the
bathroom; I'm always having to
go to the bathroom or pass gas.
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I don't have any problems with
loose stools or gas.
Question 13: Some kids tell us they worry about health problemslthey might have in the
future or bowel surgery they might need in the future. Are these tliings you worry about?
A
It's horrible always worrying
about what might happen to me
in the future because of this
bowel condition.
B
) never worry about such things.
'It's not an issue for me.
Question 14: Do you feel it's unfair that you have IBD?
A B
It's totally unfair that I have
IBD; I feel really bitter about it
all the time.
I'd rather I hadn't developed IBD,
but I never spend time thinking it's
unfair.
Question 15: Do you feel frustrated or angry about your bowel condition?
A
I feel very frustrated about my
bowel condition; it makes me
feel very angry all the time.
B
I don't feel angry or frustrated about
my bowel condition at all.
Question 16: Sometimes other people might try to set restrictions or rules about what
you eat or about other things that you would like to do. Do you feel that there are too
many restrictions on you because of your IBD?
A
I have so many restrictions
placed on me; it feels as if it's
not my life.
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B
I don't feel as if I have a lot of extra
rules.
j'
Question 17: How has your bowel condition affected your family?
A B
I hate what my bowel condition
has done to our family.
My family has handled my bowel
'--condition very well. It has made us
a stronger famil¥.
Question 18: Do you feel embarrassed about your bowel symptoms? (For example
about having to use a public washroom or going to the washroom a lot or passing gas).
A
I do almost anything to avoid
using a washroom when people
are around; You can't imagine
how embarrassing it is to always
have to use the washroom.
B
I don't feel I have any reason to be
embarrassed; that's not something
that bothers me.
Question 19: Being young is a time for having fun. Does your bowel condition get in
the way?
A
I can't remember the last time I
had fun; I feel like I'm always
missing out on just having fun.
B
I have lots of fun times.
Question 20: Do you think your bowel condition makes it harder for you to make and
have friends?
A
It's hard for me to make friends;
I feel as if I don't have any.
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B
I have good friends; we spend a lot
of time together.
Question 21: How much are you bothered by bleeding with a bow~11 movement?
A
I'm very upset or scared by the
bleeding I have been having.
B
That's not a problem. I may pass
~lood, but it's nothing I worry
about.
Question 22: How much do you worry about having an accident and not making it to
the washroom?
A
That's my worst fear. I often
don't go out because of it. I can't
go anywhere without knowing
exactly where the washrooms
are.
B
I don't have to get to the washroom
fast; that's not a problem for me.
Question 23: How much do you feel sick to your stomach?
A B
I feel like I'm always sick to my
stomach.
I never feel sick to my stomach.
Question 24: Does your bowel condition leave you feeling stressed out?
A
I'm really stressed out; I've had
about all I can take.
III
B
I don't feel stressed; I'm pretty
relaxed.
i.'
Question 25: Do you worry about tests, investigations or treatments you have for your
bowel condition? (For example Xrays, blood tests, IV's, colonoscopies).
A
I worry for days ahead of time
about tests and treatments I have
to have.
B
These things don't ~other me.
don't worry about them.
Question 26: Do you think about your life when you are grown up? Do you worry that
your bowel condition will get in the way of you having the job you want, or getting
married and having a family?
A
I used to have a lot of hopes and
dreams about what I would do in
the future; but now there's no
point.
B
I'm pretty hopeful about the future;
I don't worry about those things.
Question 27: Do you feel kids treat you as different because of your bowel condition?
Do you feel teased or not understood?
A
Kids treat me like some sort of
freak; they talk about me behind
my back or tease me.
B
I'm not treated any differently than
anyone else.
Question 28: Do you feel generally happy with your life, or have you been feeling sad
and depressed?
A
I feel very down and depressed.
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B
I feel very happy with my life.
j,'
Question 29: Do you worry that your bowel condition gets in the way of going out on
dates or having a boyfriend or girlfriend?
A
That's something that bothers me a
lot; I feel as if no one would ever
want to go out with me. I know that
a date wouldn't go well, if I had one.
B
f-don't have any nroblem with that;
I have a good so~ial life.
Question 30: Do you keep your bowel condition a secret from other people?
A
I'd never tell anyone I have IBD;
I'd do anything to keep it secret.
B
Tdon't mind people knowing that I
have IBD; it's nothing to be
ashamed of.
Question 31: Do you have problems traveling or going away for a holiday because of
your IBD?
A
I couldn't have a 1oliday. I'd
just have to stay home.
Traveling would be awful.
Question 32: How do you feel in general?
A
I just don't feel well at all. I'm
not up for much.
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B
I don't have any problems traveling
or going on holiday.
B
I feel generally very well.
Question 33: Does your bowel condition get in the way of playing sports the way you
would like to? .
A
I would love to play sports, but I
can't at all because of my bowel
condition.
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B
That's not a problem for me. I can
play'~md enjoy sports jf I want to. My
bowel condition doesp't interfere at all.
Appendix E
Univariate Analysis
, Chi-SquareP Value
(2~_ed...:..) _
Table E-la _Uni~ariate~alysis_: Catego.:i.cal Variables (Complete Set [n=122..,;lJ_/4...:..) _
. ._._ .. Disea~ Severity ... _...__
Variable I II III IV
_~~ _ (0=38) (0=29) (0=20
Female Gender 10 15 10 0.385 3.046
Initial Hospitalization (Yes) 12 12 13 0.004 13.486
Initial Steroids (Yes) 14 14 20 13 0.019 10.004
Initial Response
(PartiallNo Response vs
Complete Response)
14 22 <0.001 23.023
Disease Location
Small Bowel Only 4 0.913 0.528
Small/Large Bowel 14 21 17 10 0.449 2.651
Large Bowel Only 13 0.081 6.720
Positive Family History ofIBD 8 (n=32) 12 (n=36) 13 (n=29) 3 (n=19) 0.153 5.274
I-quiescent, II-mild~III-moderate, IV-severe.
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p Value r 2
~_=--..L.-
0.684 0.013
0.183 0.040
0.009 0.094
<0.001 0.129
0.764 0.010
0.459
Age at Diagnosis (years) 12.76 (2.82) 13.07 (2.19) 13.48 (1.93) 13.23 (2.49)
Baseline ESR (mm/hr) 45.83 (23.12) 44.24 (19.18) 49.45 (28.62) 58.40 (28.13)
Baseline Albumin (g/L) 33.77 (4.43) 33.13 (5.30) 31.86 (4.71) 29.33 (4.71)
Baseline PCDAI 33.07 (14.73) 33.95 (10.65) 42.24 (16.29) 46.38 (14.13)
Baseline PlateJcts (1 09/L) 440.60 (135.03) 432.74 (133.17) 465.17 (114.54) 452.] 0 (127.58)
Duration of Symptoms (months) 11.13 (13.91) 8.14 (8.30) 9.78 (11.36) 6.48 (10.73)
Mean (SD) -~
I-quiescent, II-mild, III-moderate, IV-severe.
Table E-1b U~ariate An~lysis: Cont~~s_yariables (Complete Set [n=122]_/4...;;.) _
__. ._ _ __. Dise~se Se'yeri~ .. ...__._..__
Variable I II III IV
. ~35) ~~ (n=29) (n=20)
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Table E-2a. -ynivariate Analysis: Categorical V~iables (All Set [n=132]/2)
Variable QuiescentlMild Moderate/Severe P Value Relative Risk 95% Confidence
Disease Disease (2-sided) Interval
(!!-=7~)_ .~_ .__ ._.__f!!=~~)
Female Gender 28 20 1.000 1.029 0.674 - 1.572
It
Initial Hospitalization 19 28 0.002 1.948 1.309 - 2.898
Initial Steroids 29 36 0.001 2.062 1.313 - 3.237
Initial Response 17 22 0.021 1.639 1.106 - 2.427
(PartiallNo Response vs
Complete Response)
Disease Location
Small Bowel Only 18 13 1.000 1.033 0.641 -1.664
Small/Large Bowel 38 30 0.482 1.176 0:177 - 1.780
Large Bowel Only 21 9 0.207 0.680 0.377 - 1.225
Positive Family History of IBD 22(n=73) 17 (n=53) 0.847 1.039 0.749 - 1.442)
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Table E-2b Univariate Analysis: Continuous Variables (All Set [n=132]/2)
Variable QuiescentlMild Moderate/Severe p Value
Disease Disease (if Variances
__....~_______. . . ~ !!~_!_~(§_~L ~ J!t<!_J~~1. ._._~ ~q~_!L_.__
Age at Diagnosis (years) 78, 12.73 (2.63) 54, 13.43 (2.07) 0.104
Baseline ESR (mm/hr) 76,44.58 (20.73) 50,53.00 (28.19) 0.056
Baseline Albumin (g/L) 77,33.32 (4.89) 51,30.95 (4.79) 0.008
Baseline PCDAl 7633.55 (12.70) 51,43.48 (15.57) <0.001
Baseline Platelets (109/L) 77,433,43 (137.93) 51,459.59 (116.50) 0.267
Duration of Symptoms (months) 78, 9.96 (11.91) 54, 8.74 (11.07) 0.552
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p Variances not
equal
0.0903
0.073
0.008
<0.001
0.251
0.547
Variable Chi-Square
Female Gender 13 15 10 10 0.621 1.772
Initial Hospitalization 7 12 15 13 0.004 13.173
Initial Steroids 14 15 23 13 0.010 11.416
Initial Response 3 14 8 14 <0.001 23.476
(PartiallN0 Response vs
Complete Response)
Disease Location
Small Bowel Only 8 10 9 4 0.880 0.670
Small/Large Bowel 17 21 20 10 0.586 1.934
Large Bowel Only 13 8 3 6 0.074 6.925
-
Positive Family History of IBD 10 (n=35) 12 (n=38) 13 (n=33) 4 (n=20) 0.508 ~323- -'
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_T~ble E-3b Univariate Analysis: Continuous Variables (All Set [n=132]~12
Disea~ Severi!y ...__..__ 2
Variable I II III IV p Value r
ll, x (SD) ll, x (SD) ll, x (SD) ll, x (SD)
Age at Diagnosis (years)
Baseline ESR (mm/hr)
Baseline Albumin (giL)
Baseline PCDAI
Baseline Platelets (109/L)
38, 12.66
(2.75)
37,45.08
(22.71)
37,33.73
(4.53)
36, 32.85
(14.58)
38,444.53
(130.35)
40, 12.78
(2.54)
39,44.10
(18.94)
40,32.95
(5.23)
40,34.19
(10.88)
39,422.62
(145.82)
33, 13.54
(1.83)
30,49.40
(28.12)
31,32.00
(4.61)
31,41.61
(16.39)
31,464.42
(110.69)
21,13.24
(2.43)
20, 58.40
(28.13)
20,29.33
(4.71)
20,46.38
(14.13)
20,452.10
(127.58)
0.411
0.148
0.010
0.001
0.599
0.022
0.043
0.087
0.122
0.015
Duration of Symptoms (months) 38,11.75
(14.71)
I-quiescent, II-mild, III-moderate, IV-severe.
40.8.26
(8.27)
33,9.65
(11.10)
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21,7.31
(11.14)
0.450
Appendix F - Multivariate Analysis
95% CI Percent
Concordant
------
71.1
0.987 - 1.052
0.883 - 1.040
0.913 - 4.334
0.680 - 3.038
1.474 - 6.850
1.018
0.958
1.990
1.437
3.177
Intercept
Intercept 2
Intercept 3
PCDAI
Albumin
Initial Hospital (Yes)
Initial Steroids (Yes)
Initial Response (Pat1iallNo Response)
Table F Muliv~riate Analysis: Logistic Regression Models (Complete Set [n=122]/4)
Covariate Regression Standard p Odds
Coefficient Error .~~_ Ratio _c _
2.157 1.744 0.216
0.599 -" 1.733 0.119
-0.872 1.737 0.252
0.019 0.016 1.310
-0.043 0.042 1.073
0.344 0.199 2.991
0.182 0.191 0.904
0.578 0.196 8.700
Intercept
Intercept 2
Intercept 3
PCDAI
Initial Hospital ('{es)
Initial Response (Pa11iallNo Response)
Intercept
Intercept 2
Intercept 3
PCDAI
Initial Response (PartiallNo Response)
0.188 0.555 0.735
-1.344 0.567 0.018
-2.799 0.610 <0.001
0.0330 0.013 0.012
0.3195 0.198 0.106
0.5880 0.194 0.003
-0.176 0.500 0.724
-1.685 0.521 0.001
-3.119 0.574 <0.001
0.040 0.012 0.001
0.654 0.191 0.001
69.7
1.033 1.007 - 1.073
1.894 0.873 - 4.110
3.241 1.512 - 6.946
67.3
~
1.041 1.016_-1:06-0 ..
3.699 1.748 - 7.828
Intercept
Intercept 2
Intercept 3
PCDAI
-0.628
-2.051
-3.407
0.044
0.470 0.181
0.500 <0.001
0.560 <0.001
0.012 0.003
------
1.045
60.8
1.020 -1.070
-----
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Table 0-1
Appendix G - Validation Analysis: Hospitalization
Construct validity testing (4 Category)
Construct Analysis p
Disease severity should reflect total length of
hospitalization
Disease severity should reflect length of
hospitalization, excluding hospitalization at diagnosis
Disease severity should reflect number of
hospitalizations
Disease severity should reflect quality of life, as
measured by IMPACT scores at one year after
diagnosis
Correlation between disease severity and total length of 0.43 <0.0001
hospitalization
Correlation between disease severity and total length of 0.47 <0.0001
hospitalization, excluding hospitalization at diagnosis
Correlation between disease severity and number of 0.43 <0.0001
hospitalizations
Correlation between disease severity and quality of life, -0.39 0.043
as measured by IMPACT scores at one year after
diagnosis
Disease severity should reflect quality of life, as
measured by IMPACT scores at six months after
diagnosis
Correlation between disease severity and quality of life, .' -0.59
as measured by IMPACT scores at six months after
diagnosis
0.010
Disease severity should reflect disease activity over
time, as measured by mean PCDAI scores at 6 and 12
months
Disease severity should reflect linear growth, as
measured by change in z-scores from end of first year
and diagnosis
Correlation between disease severity and disease 0.49 <0.0001
activity over time, as measured by mean PCDAI scores
at 6 and 12 months ... ....
Correlation between disease severity and linear growth, -0.16 0.082
as measured by change in z-scores from end of first
year and diagnosis
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p ValueF
Table G-2 Valid~tion Analysis: ~sp,-i_ta_li_z_at_io_n _. _
_______ Pls~~e_~~~__
Variable I II III IV
(n=35) <!t=~ (0=29) __(n=_2_0.£-( _
Total Days Hospitalized 1.97 (5.61) 8.00 (16.11) 11.14 (14.75) 20.10 (17.82) 7.527
Days Hospitalized Excluding 0.00 (0.00) 2.95 (8.25) 5.83 (10.65) 10.85 (13.77) 6.923
Hospitalization at Diagnosis
Number of Hospitalizations 0.17 (0.38) 0.71 (1.04) 1.07 (1.33) 1.45 (1.19) 7.927
Mean (SD)
I-quiescent, II-mild, III-moderate, IV-severe
<0.001
<0.001
<0.001
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Table 0-3 Validation Analysis: Mean PCDAI Scores
_.. _. Disease Sev~l.~._
Variable I II III IV
___________.__ .-1n=28) (n=25) __{!1,=21) (n=~
F p Value
Mean PCDAI Scores
(6 and 12 months)
4.24 (3.42) 12.30 (8.12) 13.93 (10.01) 18.67 (13.51) 10.435 <0.001
Mean (SD)
I-quiescent, II-mild, III-moderate, IV-severe
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Table G-4 Validation Analysis: Growth
Disease Severity
Variable I II III IV
(n=35) (n=38) (n=29) (n=20)
Height at Diagnosis (z-score) -0.48 (1.09) -0;.77 (1.40) -0.71 (0.86) -0.70 (1.28)
Height at One Year (z-score) -0.28 (l.03) -0.67 (1.17) -0.85 (0.82) -0.63 (1.39)
Change in Height Over One Year 0.20 (0.51) 0.10 (0.62) -0.14 (0.30) 0.07 (0.51)
(Delta z-score)
Mean (SD)
I-quiescent, II-mild, III-moderate, IV-severe
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F P Value
0.399 0.754
1.537 0.208
2.471 0.065
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